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ABSTRACT  
A unified strategy for enantioselective total synthesis of all stereoisomers of the [2+2] family of quadrigemine 
alkaloids is reported. In this approach, two enantioselective intramolecular Heck reactions are carried out at the 
 3 
same time on precursors fashioned in four steps from either meso- or (+)-chimonanthine to form the two critical 
quaternary carbons of the peripheral cyclotryptamine rings of these products. Useful levels of catalyst control 
are realized in either desymmetrizing a meso precursor or controlling diastereoselectivity in elaborating C2-
symmetic intermediates. None of the synthetic quadrigemines are identical with alkaloids isolated previously 
and referred to as quadrigemines A and E. In addition, we report improvements in our previous total syntheses 
of (+)- or (–)-quadrigemine C that shortened the synthetic sequence to 10 steps and provided these products in 
2.2% overall yield from tryptamine. 
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1. Introduction 
Alkaloids composed of multiple 1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole (cyclotryptamine or 
pyrrolidinoindoline) units have been isolated from a variety of natural sources, including bacteria, fungi, plants 
and amphibians (Figure 1).1  In the predominant family of these alkaloids, cyclotryptamine units are joined at 
their benzylic C3a carbon to generate dimers, trimers and higher-order oligomers. In this linkage, two types of 
quaternary stereogenic centers are produced: (a) vicinal quaternary carbons joining benzylic (C3a) quaternary 
stereocenters of two cyclotryptamine units, and (b) aryl-substituted quaternary carbons linking the peri (C7) 
carbon of one pyrrolidinoindoline unit and the benzylic quaternary stereocenter of another. Both types of 
quaternary stereocenters present formidable challenges for stereocontrolled synthesis.  As a result, when our 
efforts in this area began in 1995, no stereocontrolled methods were available for linking cyclotryptamine 
fragments at C3a.2  In the intervening years, this challenging problem in total synthesis has been addressed by a 
number of researchers and many imaginative methods are currently available.2,3 Nonetheless, stereocontrolled 
total synthesis of the more complex members of this group remains largely an unmet challenge.4 
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     Figure 1. A pyrrolidinoindoline fragment and the connectivity of the chimonanthine and quadrigemine 
alkaloids. 
The first cyclotryptamine alkaloids containing four tricyclic units, quadrigemines A and B, were reported by 
Perry and Smith in 1978 from the leaves of Hodgkinsonia frutesecens.5,6 Analysis of quadrigemine A revealed a 
base peak of m/z 344 corresponding to half the molecular weight of quadrigemine A along with ions m/z 345 
and 690 in the EI mass spectrum. In comparison, quadrigemine B showed a parent ion of m/z 516, along with 
ions m/z 690, 517, and 172. The difference in fragmentation patterns corresponds to the location of the labile s-
bond connecting the 3a¢–3a²-vicinal quaternary carbon centers of the chimonanthine subunit. 7  This 
fragmentation pattern has been used to designate the two groups of constitutional isomers: the [2+2] and [3+1] 
quadrigemine alkaloids (Figure 1).8  
Quadrigemines A,5 C9, and E10 are the three reported members of the [2+2] quadrigemine family. The 
complex NMR spectra and amorphous nature of these higher-order polypyrrolidinoindoline alkaloids has made 
determination of their three-dimensional structures particularly difficult. The relative and absolute configuration 
of only quadrigemine C (1) is known with certainty (Figure 2). Sévenet, who initially isolated quadrigemine C 
from an extract of Psychotria oleoides found in New Caledonia,9a provided evidence for the R absolute 
configuration of the two outer quaternary carbons of 1 by chemical correlation with hodgkinsine, whose 
absolute and relative configuration had been determined by single-crystal X-ray analysis.9b,11 However rigorous 
proof of the absolute configuration of the central chimonanthine unit was not secured until the enantioselective 
total synthesis of (–)-quadrigemine C was reported by our group in 2002.4 The optical rotations reported for 
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quadrigemines A, C, and E in alcoholic solvents ([a]D A, +32 (EtOH);5 C, +40 (MeOH);9d E, +33 (EtOH)10 are 
similar; suggesting that these alkaloids, which were isolated by different laboratories, could be identical.12 
Resolving this issue from the published NMR characterization data is impossible, because of differences in the 
reported NMR solvent and spectrometer field strength. Even if directly comparable data were available for 
evaluation, the presence of several interconverting low-energy conformations of these alkaloids results in broad 
peaks on the NMR timescale at 298K. Attempts to coalesce these signals at elevated temperatures are typically 
compromised by the lability of s-bond connecting the vicinal quaternary carbons.7 Cooling the NMR sample 
can result in enhanced resolution of the major conformers, as is the case for quadrigemine C;4,9c however, fully 
analyzing these complex spectra is challenging.  Quadrigemines A and E, if different from quadrigemine C, 
could be one of six C2-symmetric stereoisomers (5, 6, 7 and their enantiomers, Figure 2). Overall there are ten 
possible [2+2] quadrigemine stereoisomers: 4 enantiomeric pairs and two meso compounds (Figure 2). 
 
Figure 2. Structure of quadrigemine C and six stereoisomers. 
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In an attempt to clarify the structures of quadrigemines A and E, we initiated stereocontrolled total syntheses 
of the remaining chiral members of the [2+2] quadrigemine alkaloid family. Moreover such an investigation 
would allow us to investigate the degree of catalyst control achieved in enantioselective Heck cyclizations 
carried out with C2-symmetric intermediates; in our original total synthesis of quadrigemine C (1), the pivotal 
enantioselective cyclizations were realized with a meso precursor. During these studies, several improvements 
to our original synthesis of quadrigemine C were attained, allowing the synthetic route to be shortened and the 
overall yield improved. Finally, with access to an expanded group of [2+2] quadrigemines, the effect of relative 
and absolute configuration on their antitumor activity was evaluated. 
2. Results and discussion 
2.1 Inside-out approach to the [2+2] quadrigemines 
In the approach we developed to synthesize members of the [2+2] family of quadrigemines, the outer two 
pyrrolidinoindoline fragments are elaborated simultaneously on a functionalized chimonanthine core (Scheme 
1). The formation of decacyclic dioxindole A by double enantioselective intramolecular Heck cyclization of 
dibutenanilide B is the pivotal step in this sequence.13 The Heck cyclization precursor B is formed by a double 
Stille coupling of a chimonanthine diiodide C with two equiv of stannane 8, an intermediate that contains all the 
heavy atoms of a cyclotryptamine fragment. The natural products meso-chimonanthine and its enantiopure C2-
symmetric stereoisomers, which are now readily available by stereocontrolled chemical synthesis,14,15 serve as 
the starting point of the synthetic sequence. 
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Scheme 1. Retrosynthetic analysis: an inside-out synthetic strategy. 
 
2.2 Enantioselective synthesis of [2+2] quadrigemines having a meso core  
In our initial synthesis of quadrigemine C,4 meso-chimonanthine (9) was prepared from oxindole and isatin 
in 13 steps and ~30% overall yield by a stereocontrolled sequence that we had defined previously.14b To 
expedite access to larger quantities of meso-chimonanthine (9), we have since adopted the non-stereocontrolled 
oxidative dimerization method reported by Takayama and co-workers.16 This method involves the oxidative 
dimerization of Nb-carbomethoxytryptamine with phenyliodine(III) bis(trifluoroacetate) and a subsequent 
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 8 
reduction with Red-Al® to generate meso-chimonanthine (9) in two steps and 20–30% yield. Willis and co-
workers recently improved this procedure by enhancing overall scalability and purification of product 9.17 
Utilizing our previously published procedure, meso-chimonanthine diiodide 10 was prepared from meso-
chimonanthine in three steps and 66% overall yield by di-Boc protection, di-ortho-iodination, and removal of 
the Boc groups (Scheme 2).4 
     
Scheme 2. Optimized double-Stille cross coupling. 
 
In our first generation synthesis, the Stille cross coupling of meso-diiodide 10 with 3 equiv of stannane aryl 
triflate 8 to provide the meso-dibutenanilide 11 was achieved using a catalyst system of Pd2dba3·CHCl3, tri-2-
furylphosphine and CuI in 1-methyl-2-pyrrolindoline (NMP).4,18 This Stille coupling was sluggish, requiring 
long reaction times (>36 h) at room temperature, and provided variable yields of 11 (55–71%). In the hope of 
both accelerating the rate of the reaction and improving the overall yield, several additional conditions for 
accomplishing this double cross coupling were investigated. Attempts to accelerate the reaction rate by 
increasing the reaction temperature were thwarted by slow decomposition of the aryl triflate functionality of 
stannane triflate 8. The use of fluoride ion (CsF) to accelerate the reaction did not have a substantial effect on 
improving the overall conversion.19 The use of copper(I) thiophene-2-carboxylate (CuTC),20 or CuTC in 
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addition to [Ph2PO2][NBu4]21 did accelerate the reaction rate, but did not improve the yield. After further 
experimentation, a Stille coupling procedure reported by Corey and co-workers using Pd(PPh3)4/CuCl/LiCl was 
found to be optimal.22 Thus, reaction of meso-diiodide 10 with 3 equiv of stannane aryl triflate 8, 0.5 equiv of 
Pd(PPh3)4, 5 equiv of CuCl, and 6 equiv of LiCl in DMSO at room temperature for 20 h provided meso-
dibutenanilide 11 in 96% yield.  
As the outer pyrrolidinoindolines of quadrigemine C (1) have the same absolute configuration, our strategy 
was to utilize an enantioselective intramolecular Heck reaction to access the desired C1-symmetric dioxindole 
stereoisomer using a two-directional synthesis strategy.23 In accordance with the Horeau principle, a double 
enantioselective transformation has the potential to amplify the enantiopurity of the product over that provided 
by a single enantioselective transformation.24 Although the overall yield of the desired product is diminished, 
the product’s enantiomeric purity should by equal to the square of the enantioselectivity of a single reaction. 
Several conditions were examined to optimize the double enantioselective Heck cyclization of meso-
dibutenanilide 11 (Scheme 3, Table 1). Of the diphosphine ligands screened, (R)-tol-BINAP in MeCN provided 
superior diastereo- and enantioselection, providing pentacyclic dioxindole 12 and its two meso stereoisomers in 
a ratio of 9.3:2.0:1.0. The C1-symmetric product 12 (62%, 90% ee) and the meso products 13 and 14 (14% and 
7% respectively)25 were separated by preparative HPLC. The related enantioselective Heck cyclization 
employed in the enantioselective synthesis of the nonacyclic cyclotryptamine alkaloids hodgkinsines A and B 
from meso-chimonanthine gave a 1:1 ratio of these products in high yield and 79 and 83% ee.26,27 As the 
observed enantiomeric purity of the C1-symmetric product 12 (90% ee) is somewhat less than the predicted 
(98% ee) from the results in the hodgkinsine series, it can be inferred that the two enantioselective 
intramolecular Heck reactions are not completely independent. It is important to note that representing these 
molecules in two dimensions is deceiving. This decrease in enantioselectivity from the predicted model most 
likely results from stereoinduction across the meso-chimonanthine backbone during the second Heck 
cyclization. A sense that such interactions would be possible can be gleaned from a three-dimensional model of 
quadrigemine C (Figure 3). Carrying out the cyclization of ditriflate 11 under identical conditions using (S)- 
 10 
rather than (R)-BINAP gave dioxindole ent-12 in 80% yield; the higher selectivity in forming the C1-symmetric 
product in this double enantioselective Heck reaction suggests that catalyst and substrate control are matched 
with the catalyst formed from (S)-BINAP. 
 
Scheme 3. Double enantioselective Heck cyclization of meso-dibutenanilide 11 (one of the meso stereoisomers 
has the S,S,R,R absolute configuration and the other the R,S,R,S absolute configuration).  
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Table 1. Optimization of the double enantioselective Heck cyclization of meso-dibutenanilide 11. 
Entry Conditionsa Solvent ds ratio (12:13:14)b % ee 12b 
1 
2 
3 
4 
5c 
6 
7 
8 
9 
10  
(R)-BINAP 
(R)-BINAP 
(R)-BINAP 
(R)-BINAP 
 (S,S)-BDPP 
(R)-tol-BINAP 
(R)-tol-BINAP 
(R)-tol-BINAP 
(R)-tol-BINAP 
(R)-tol-BINAP 
THF 
DMA 
MeCN 
PhMe 
THF 
THF 
DMA 
NMP 
NMP 
MeCN 
2.8:1.7:1.0 
2.5:1.0:1.1 
3.5:1.7:1.0 
3.1:2.7:1.0 
2.4:1.0:1.5 
7.2:2.0:1.0 
6.7:1.2:1.0 
5.6:1.2:1.0 
5.1:1.7:1.0  
9.3:2.0:1.0 
65  
64  
80  
54  
35  
85  
81  
80  
79  
90  
a 50 mol% Pd(OAc)2, 100 mol% phosphine ligand, 4 equiv 1,2,2,6,6-pentamethylpiperidine (PMP), 80 °C; b 
ratio determined by HPLC; c ent-12 was formed preferentially.  
 
 
Figure 3. Model of a low-energy conformation of quadrigemine C.28 
In our original synthesis of quadrigemine C, diene disulfonamide 12 was hydrogenated at 100 psi using 
Pd(OH)2/C in 10:1 EtOH-MeOH at 80 °C to saturate the two double bonds.4 These conditions often resulted in 
yields of the tetrahydro product 15 that varied depending upon the batch of substrate and catalyst.29 Since our 
initial report, we discovered that including 8 equiv of K2CO3 resulted in enhanced reproducibility for this 
transformation, which we attribute to preventing any acid-catalyzed decomposition.30,31 Additionally, increasing 
the hydrogen pressure to 1000 psi in EtOH at 80 °C helped to ensure full conversion. Using this procedure, 12 
reproducibly was transformed to its tetrahydro congener in yields of 90–95% (Scheme 4). Exposure of this 
 12 
unpurified intermediate to a large excess of Na (50 equiv) in THF/NH3 containing 4 equiv of tert-butanol for 20 
min at –78 °C, followed by quenching with NH4Cl and HPLC purification afforded (–)-quadrigemine C (1). 
Modification of our previous conditions by the incorporation of tert-butanol32led to significant improvements in 
reproducibility, reliably yielding (–)-quadrigemine C in 22–24% for the two steps 
 
Scheme 4. Completion of an optimized total synthesis of quadrigemine C. 
The improvements made in this second generation synthesis of (–)-quadrigemine C shortened the synthetic 
sequence to 10 steps and provided (–)-quadrigemine C (1), [a]23D –67 (c = 0.2, CHCl3) and [a]23D –30 (c = 0.2, 
EtOH), in 2.2% overall yield from tryptamine. Synthetic (–)-quadrigemine C showed physical properties (1H 
NMR, 13C NMR, HRMS) consistent with those of the natural product,9a–d and was indistinguishable from an 
authentic sample by HPLC and CD analysis.33,34 Moreover, heating a sample of (–)-quadrigemine C at 100 °C in 
the presence of dilute aqueous acetic acid gave synthetic (–)-psycholeine (16) in 38% yield, which showed 1H 
NMR and 13C NMR spectra identical to those reported for the natural product.9a–c Using the optimized 
procedures described herein, ent-(+)-quadrigemine C (2), [a]23D +70 (c = 0.12, CHCl3) and [a]23D +19 (c = 0.15, 
EtOH), as well as the two meso-quadrigemine congeners 3 and 4 were prepared in an identical fashion (see 
summary in Table 3). 
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2.3 Enantioselective total synthesis of [2+2] quadrigemines having a C2-symmetric chimonanthine core 
The starting material for our studies in this series was (+)-chimonanthine (17), which we prepared in gram 
quantities from a-methoxycarbonyl-L-tryptophan methyl ester using the 8-step biomimetic sequence developed 
by Movassaghi and co-workers.14c The necessary C2-symmetric diiodide 18 was synthesized, as previously 
optimized in the meso-chimmonanthine series, by di-Boc protection of the aniline nitrogens, di-ortho-
iodination, and removal of the Boc groups to provide C2-symmetric diiodide 18 in 72% yield. The di-Stille cross 
coupling of diiodide 18 with stannane 8 using the recently optimized conditions provided C2-symmetric 
dibutenanilide 19 in 98% yield. 
 
Scheme 5. Synthesis of the Heck cyclization precursor in the C2-symmetric series. 
 
 We turned to examine the double enantioselective Heck cyclization in the C2-symmetric series, wherein the 
chiral substrate would influence diastereoselectivity.31,35 To examine the inherent substrate bias, the double 
enantioselective Heck cyclization of ditriflate 19 was carried out initially using rac-tol-BINAP, which resulted 
in modest substrate control to give the C2- and C1-symmetric dioxindole products 20 and 21 in a 1.0:2.3 ratio. 
Utilizing the catalyst generated from 0.5 equiv Pd(OAc)2, 1.0 equiv of (R)-tol-BINAP and 4 equiv of 1,2,2,6,6-
pentamethylpiperidine (PMP) at 80 °C, various solvents were evaluated. A decrease in solvent polarity from N-
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methylpyrrolidinone (NMP) to THF resulted in a decrease in diastereoselectivity (entries 2–4, Table 2). To 
some surprise, diastereoselection was inverted in toluene, giving the C1-symmetric stereoisomer 21 as the major 
product. The combined yield of the decacyclic dioxindole products 20 and 21 produced in NMP was lower 
(58%) than we had anticipated. Analysis of the crude product mixture by mass spectrometry identified the 
formation of byproducts in which one of the pyrrolidinoindoline nitrogens had been acetylated.  This product is 
a likely culprit of the decreased selectivity and undoubtedly arose from the formation of acetic anhydride during 
the reduction of Pd(OAc)2 by the phosphine ligand.36 Inclusion of 10 equiv of N-methyl-p-anisidine as a 
scavenger for Ac2O diminished formation of the acetylated byproducts, providing the C2-symmetric dioxindole 
20 and its C1-symmetric stereoisomer 21 in 4.3:1 ratio and 79% combined yield. Identical Heck cyclization of 
19 using Pd-(S)-tol-BINAP afforded C2-symmetric (S,R,R,S) dioxindole 22 and dioxindole 21 in a 2:1 ratio and 
81% yield. The diastereomeric dioxindole products products were separated by silica gel chromatography and 
subsequently processed independently to their respective [2+2] quadrigemines.  
 
Scheme 6. Diastereoselective double Heck cyclization of C2-symmetric dibutenanalide 19. 
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Table 2. Diastereoselective double Heck cyclization in the C2-symmetric series. 
 
Entry Conditionsa Solvent ds ratio (20:21; C2:C1)b 
1 
2 
3 
4 
5 
rac-tol-BINAP 
(R)-tol-BINAP 
(R)-tol-BINAP 
(R)-tol-BINAP 
(R)-tol-BINAP 
NMP 
NMP 
MeCN 
THF 
PhMe 
1.0:2.3 
4.3:1.0 
3.0:1.0 
2.5:1.0 
1.0:2.3 
a 50 mol% Pd(OAc)2, 100 mol% phosphine ligand, 4.0 equiv 1,2,2,6,6-pentamethylpiperidine (PMP), 80 °C; b 
ratio determined by HPLC 
Utilizing the procedures developed during our optimized total synthesis of quadrigemine C (1), pentacyclic 
dioxindole products 20–22 were hydrogenated (1000 psi) with Pd(OH)2/C in EtOH at 80 °C.  Subsequent 
exposure of the resulting tetrahydro products to a large excess of sodium (50 equiv) in THF/t-BuOH/NH3 at –78 
°C for 20 min, followed by quenching with NH4Cl provided the respective [2+2] quadrigemine products 5–7, in 
23–29% yield for the final two steps. The yields of the final steps in the total syntheses of the quadrigemine 
stereoisomers prepared in this study and the optical rotations at the sodium D line of the quadrigemine products 
are summarized in Table 3. The CD spectra of synthetic quadrigemines 1, 2, 5–7 are shown in Fig. 4. 
Table 3. Yield of the final two steps in the synthesis of [2+2] quadrigemines and their optical rotations. 
Starting Material Product Yield (over 2 steps) [a]Da 
12 
ent-12 
13 
14 
20 
21 
22 
1 (R,S,R,R)-quadrigemine C 
2 (S,R,S,S)-ent-quadrigemine C 
major meso-quadrigeminec,e 
minor meso-quadrigemined,e 
7 (R,R,R,R) 
6 (S,R,R,R) 
5 (S,R,R,S) 
22–24% 
24% 
40% 
16% 
23% 
29% 
29% 
–30 (–67)b 
+20 (+70)b 
– 
– 
+277 
+140 
+231 
 
a [a]D taken in EtOH. b [a]D taken in CHCl3. c The dodecacyclic product resulting from transformation of the 
major meso Heck product 13; d The dodecacyclic product resulting from transformation of the minor meso Heck 
product 14; e The relative configuration could not be confirmed, the product is either meso quadrigemine 3 or 4. 
 
 16 
 
a all data taken ~2.9 x 10–4 M in EtOH 
 
           Figure 4. Circular dichroism of [2+2] quadrigeminesa 
 The optical rotation data and 13C NMR spectra for the synthetic quadrigemines 5–7 confirm that these C2-
symmetic [2+2] quadrigemines are not identical to natural quadrigemines A and E.37 Moreover, HPLC 
comparison of these products with a crude isolate of Psychotria muscosa showed that these synthetic 
quadrigemines were not identical to the structurally uncharacterized higher-order polypyrrolidindoline alkaloids 
identified in this sample by Verotta and coworkers. 38,39 These findings suggest that quadrigemines A and E 
could be identical to quadrigemine C. 
2.4 Antitumor evaluation 
  A diversity of biological activities–antiviral, antibacterial, antifungal, and anticandidal–are described for 
quadrigemine alkaloids.1c In addition, selected quadrigemines are reported to be analgesics,31,38,40 antagonists of 
the somatostain receptor (SRIF),9b inhibitors of human platelet aggregation,41 and to display cytotoxic activity 
against solid and blood tumors.42 To gain some insight into the relationship between the three-dimensional 
structures of higher-order polypyrrolidinoindoline alkaloids and their antitumor activity, the in vitro 
cytotoxicities of the [2+2] quadrigemines prepared in this study, and several additional polypyrrolindoline 
-45
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25 350345340335330325320315310305300295290285280275270265260255250245240235230225220215210205200
C
D
 (m
de
g)
wavelength (nm)
RSRR - quadrigemine C (1)
SRSS - ent-quadrigemine C (2)
SRRS - (5)
SRRR - (6)
RRRR - (7)
 17 
alkaloids prepared in our laboratories (depicted in Figure 5), were determined against two invasive cancer cell 
lines: DU145 (human prostate cancer) and A2058 (human melanoma). Several trends emerge from the 
cytotoxicity data summarized in Table 4: (a) In general, cytotoxicity increases as a function of molecular weight 
(increasing number of pyrrolidinoindoline units); only one dodecacyclic alkaloid (the minor meso-quadrigemine 
4, entry 3) was less active than the nonacyclic alkaloids (entries 7–11). (b) Relative configuration of higher-
order polypyrrolidinoindolines makes only a minor contribution to cytotoxicity. For example, (–)-quadrigemine 
C is only 2–4 fold more active than the other [2+2] quadrigemine alkaloids. (c) (–)-Psycholeine (16), the isomer 
of (–)-quadrigemine C having a calycanthine core, showed little cytotoxicity (entry 7). The first two of these 
trends are in accord with cytotoxicity data reported previously for a few cyclotryptamine alkaloids.42 
 
Figure 5: Additional pyrrolidinoinoline alkaloids. 
 
Table 4. Cytotoxic activity against prostate cancer (DU145) and melanoma (A2508) cell lines (IC50).a 
 
Entry Compound DU145 A2058 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
 
(–)-quadrigemine C (1) 
meso-quadrigeminea,c 
meso-quadrigemineb,c 
(S,R,R,S)-quadrigemine (5) 
(S,R,R,R)-quadrigemine (6) 
(R,R,R,R)-quadrigemine (7) 
(–)-psycholeine (16) 
(–)-hodgkinsine   
(–)-hodgkinsine B  
(–)idiospermuline  
(–)-epi-idiospermuline  
meso-chimonanthine (9) 
(–)-chimonanthine (ent-17) 
(–)-calycanthine  
2.2 µM 
4 µM 
>10 µM 
8.8 µM 
4.7 µM 
5.0 µM 
>10 µM 
7.2 µM 
8.0 µM 
>10 µM 
>10 µM 
>10 µM 
>10 µM 
>10 µM 
 
1.7 µM 
5 µM 
>10 µM 
4.1 µM 
3.5 µM 
4.1 µM 
>10 µM 
7.2 µM 
8.1 µM 
>10 µM 
>10 µM 
>10 µM 
>10 µM 
>10 µM 
 
H
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H
N
MeH
H
HN
N
MeH
H
N
MeN
N
H
N
MeH
H
HN
N
MeH
(–)-hodgkinsine (–)-hodgkinsine B
N
N
HN
H
N
Me
Me
(–)-calycanthine
Me
N
MeN
N
H
N
MeH
H
MeN
N
MeH
(–)-idiospermuline
Me
N
MeN
N
H
N
MeH
H
MeN
N
MeH
(–)-epi-3a'',epi-8a''-idiospermuline
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    a The dodecacyclic product resulting from transformation of the major meso Heck 
product 13; b The dodecacyclic product resulting from transformation of the minor meso Heck product 14; c The 
relative configuration could not be confirmed, the product is either meso quadrigemine 3 or 4. 
  
 
3. Conclusion 
The inside-out strategy (Scheme 1) that we first introduced in 2002 to synthesize (–)- (1) and (+)-quadrigemine 
C (2) is utilized in this investigation to prepare all potential stereoisomers of dodecacyclic quadrigemines 
having chimonanthine cores (Figure 2). As a prelude to these studies, two steps—the double Stille cross 
coupling to introduce the heavy atoms of the peripheral cyclotryptamine rings and the subsequent catalytic 
hydrogenation–were optimized to improve the yields and make these transformations more robust. The second-
generation total synthesis of natural (–)-quadrigemine C (1) reported herein was accomplished in 10 steps and 
2.2% overall yield from tryptamine. This short enantioselective total synthesis, and the other concise 
constructions of quadrigemine stereoisomers we report, are testaments to the power of two-directional synthesis 
strategies23 and the utility of catalytic enantioselective transformations–in this case intramolecular Heck 
reactions13–to stereoselectively generate structurally intricate polycyclic molecules. The total syntheses reported 
herein are rare examples of using two-directional strategies to stereoselectively elaborate cyclic molecules.43  
This total synthesis study showed that the previously reported alkaloids referred to as quadrigemines A5 and E10 
are not identical to any of the synthetic quadrigemine stereoisomers, and most likely are the same as 
quadrigemine C. In addition, investigations of the in vitro antitumor activities of products prepared in this study 
showed that the relative configuration of the [2+2]) family of quadrigemines influences cytotoxicity in only a 
minor way.  
4. Experimental section 
Experimental procedures and characterization data for the preparation of compounds 1, 8, 11–15 have been 
reported previously.4 
4.1 Enantioselective total synthesis of quadrigemine C (1) and ent-quadrigemine C (ent-1) 
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meso-Dibutenanilide 11. Diiodide 10 (262 mg, 0.44 mmol) and stannane 8 (1.14 g, 1.31 mmol) were combined 
in a round bottom flask and azeotroped to dryness with dry THF (3 x 6 mL). The mixture was placed under 
vacuum (1.0 mmHg) for 30 min and then pumped into an inert atmosphere (N2) drybox. A stirbar followed by 
Pd(PPh3)444 (252 mg, 0.219 mmol), LiCl (111 mg, 2.60 mmol), and CuCl (216 mg, 2.19 mmol) were added to 
the flask and the mixture was suspended in dry DMSO (15 mL). The flask was capped and stirred at room 
temperature in the drybox for 20 h. After removing the flask from the drybox, the black solution was partitioned 
between 5% v/v aqueous solution of NH4OH (20 mL) and EtOAc (30 mL) and the aqueous phase was extracted 
with EtOAc (3 x 15 mL). The combined organic layers were washed consecutively with water and brine. The 
organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The dark residue was 
purified by flash column chromatography (10 %KF/SiO245 100% CH2Cl2 ® 10:1 CH2Cl2/MeOH; product 11 
(635 mg, 96%) elutes with 3–5% MeOH in CH2Cl2 as a brown foam, which showed 1H and 13C NMR spectra 
identical to those reported.4 
Double enantioselective Heck cyclization of meso-dibutenanalide 11. A sample of ditriflate 11 (150 mg, 0.100 
mmol) was azeotroped to dryness in benzene (3 x 2 mL) in a sealable Schlenk tube and placed under vacuum 
(1.0 mm) for 1 h. To the Schlenk flask was added a stirbar, Pd(OAc)2 (23 mg, 0.10 mmol), and (R)-tol-BINAP 
(0.140 g, 0.200 mmol). The flask was evacuated and backfilled with N2 (3 x). Dry MeCN (2 mL) and 1,2,2,6,6-
pentamethylpiperidine50 (73 µL, 0.40 mmol) were added and the reaction mixture was degassed using the 
freeze–pump–thaw technique (3 cycles, liquid N2 cooling bath, 0.1 mmHg, backfill with N2). The heterogeneous 
brown-red mixture was then heated to 80 °C for 16 h.  After cooling to room temperature, the deep red solution 
was partitioned between a 20% w/w aqueous solution of NaCN (10 mL) and EtOAc (10 mL). The aqueous layer 
was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water and brine.  The 
organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was 
purified by column chromatography (SiO2: 100:0 CH2Cl2 ® 97:3 CH2Cl2/MeOH ® 94:5:1 
CH2Cl2/MeOH/NH4OH ® 89:10:1 CH2Cl2/MeOH/NH4OH) to provide a mixture of 12, 13, and 14 in a 9:2:1 
ratio (ratio determined by reverse-phase HPLC analysis). The three diastereomers could be further purified by 
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preparative reverse-phase HPLC (Phenomenex Gemini-NX, 250 x 21.2 mm), 80:20 MeCN-H2O (1% NH4OH), 
25 mL/min, UV detection at 254 nm; to afford 74 mg (62%) of 12 (rt = 30.9 min), 17 mg (14%) of 13 (rt = 37.6 
min), and 8 mg (7%) of 14 (rt = 23.7 min) as colorless foams. 
 (R,R,S,R)-Isomer 12.4 [a]28D –60, [a]28577 –62, [a]28546 –72, [a]28435 –153, [a]28405 –207 (c = 0.25, CH2Cl2). 
Major meso-isomer 13. 1H NMR (500 MHz, (CD3)2SO, 376K) d 7.49 (d, J = 7.5 Hz, 4H), 7.35 (d, J = 7.8 Hz, 
6H), 7.34–7.31 (m, 4H), 7.27–7.23 (m, 8H), 7.06–7.01 (m, 4H), 6.96 (d, J = 7.2 Hz, 2H), 6.79 (d, J = 7.8 Hz, 
2H), 6.65 (d, J = 14.3 Hz, 2H), 6.41 (br s, 2H), 5.32 (d, J = 14.2 Hz, 2H), 4.97 (d, J = 15.4 Hz, 2H), 4.90 (d, J = 
15.5 Hz, 2H), 4.25 (br s, 2H), 4.09 (s, 2H), 2.85 (s, 6H), 2.38 (s, 6H), 2.30–2.24 (m, 4H), 1.98–1.94 (m, 2H), 
1.78–1.73 (m, 2H), 1.71 (s, 6H); 13C NMR (125 MHz, (CD3)2SO, 376 K) d 175.9 (C), 148.9 (C), 143.3 (C), 
141.3 (C), 135.7 (C), 133.8 (C), 133.7 (C), 130.6 (C), 129.7 (CH), 129.3 (CH), 128.0 (CH), 127.6 (CH), 126.92 
(CH), 126.88 (CH), 126.2 (CH), 126.0 (CH), 124.0 (CH), 122.7 (C), 122.0 (CH), 118.6 (C), 116.8 (CH), 110.0 
(CH), 108.9 (CH), 82.3 (CH), 61.7 (C), 55.6 (C), 50.8 (CH2), 42.8 (CH2), 36.0 (CH2), 33.8 (CH3), 31.9 (CH3), 
20.2 (CH3); IR (thin film) 3358, 2934, 1706, 1610, 1467, 1355, 1162, 745 cm–1; LRMS-ESI (m/z) [M + H]+ 
calcd for C72H70N8O6S2H 1207.5; found, 1207.5. 
Minor meso-isomer 14. 1H NMR (500 MHz, (CD3)2SO, 376K) d 7.42 (d, J = 7.8 Hz, 4H), 7.32–7.27 (m, 6H), 
7.22 (br s, 14 H), 6.97 (br s, 4H), 6.94 (d, J = 7.6 Hz, 2H), 6.70 (br s, 2H), 6.58 (d, J = 14.3 Hz, 2H), 5.37 (d, J 
= 14.2 Hz, 2H), 4.98 (d, J = 15.8 Hz, 2H), 4.75 (d, J = 15.8 Hz, 2H), 2.90 (br s, 2H), 2.85 (s, 6H), 2.69–2.59 (m, 
2H), 2.46 (s, 6H), 2.38–2.35 (m, 2H), 2.34 (s, 6H), 2.16–2.09 (m, 2H), 2.04 (br s, 4H), 1.82–1.79 (m, 2H); 13C 
NMR (125 MHz, (CD3)2SO, 376 K) d 175.9 (C), 148.9 (C), 143.3 (C), 141.3 (C), 135.7 (C), 133.7 (C), 130.6 
(C),  129.7 (CH), 129.3 (CH), 129.2 (CH), 128.0 (CH), 127.6 (CH), 126.9 (CH), 126.5 (CH), 126.2 (CH), 125.9 
(CH), 124.0 (CH), 122.7 (CH), 122.1 (CH), 118.6 (C), 116.7 (C), 110.1 (CH), 108.9 (CH), 82.3 (CH), 61.7 (C), 
55.6 (C), 50.8 (CH2), 42.8 (CH2), 36.0 (CH3), 33.8 (CH2), 31.8 (CH3), 20.3 (CH3); IR (thin film) 3405, 2934, 
1710, 1610, 1455, 1359, 1162, 748 cm–1; LRMS-ESI (m/z) [M + H]+ calcd for C72H70N8O6S2H 1207.5; found, 
1207.5. 
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(S,R,S,S)-Isomer (ent-12). Carrying out the double Heck cyclization in similar fashion using (S)-tol-BINAP and 
77 mg (0.051 mmol) of meso-dibutenanalide 11 gave as the major product dioxindole ent-12 (51 mg, 83%): 1H 
NMR (500 MHz, (CD3)2SO, 376K)46 d 7.49–7.45 (m, 4H), 7.36–7.30 (m, 8H), 7.27–7.19 (m, 10H), 7.11 (br d, J 
= 6.4 Hz, 1H), 7.06–6.97 (m, 5H), 6.90 (br d, J = 7.7 Hz, 1H), 6.74 (br s, 2H), 6.65 (d, J = 15.0 Hz, 1H), 6.61 
(d, J = 15.8 Hz, 1H), 6.47 (br s, 1H), 6.34 (br s, 1H), 5.42 (d, J = 14.3 Hz, 1H), 5.29 (d, J = 14.3 Hz, 1H), 5.05 
(d, J = 15.8 Hz, 1H), 4.98 (d, J = 15.5 Hz, 1H), 4.85 (d, J = 15.6 Hz, 1H), 4.78 (d, J = 15.8 Hz, 1H), 4.40–4.10 
(br s, 3H), 2.88 (s, 3H), 2.83 (s, 3H), 2.66 (br t, J = 6.7 Hz, 1H), 2.52–2.48 (m, 2H), 2.38 (s, 3H), 2.36 (s, 3H), 
2.35–2.30 (m, 1H), 2.29–2.21 (m, 1H), 2.14 (s, 3H), 2.07–1.89 (m, 1H), 1.86–1.82 (m, 1H), 1.78–1.71 (m, 1H), 
1.72 (s, 3H); 13C NMR (125 MHz, (CD3)2SO, 376 K) d 176.2 (C), 176.0 (C), 150.0 (C), 149.0 (C), 143.4 (C), 
143.3 (C), 141.3 (C), 141.2 (C), 135.66 (C), 135.64 (C), 134.5 (C), 133.9 (C), 133.7 (C), 133.4 (br, C), 130.5 
(CH), 130.4 (C), 129.8 (CH), 129.5 (CH), 129.24 (2 peaks, CH), 127.93 (CH), 127.92 (CH), 127.68 (CH), 
127.65 (CH), 127.58 (CH), 127.0 (CH), 126.8 (CH), 126.7 (CH), 126.4 (CH), 126.1 (CH), 126.0 (CH), 125.95 
(CH), 124.5 (CH), 124.2 (CH), 122.8 (CH), 122.6 (CH), 122.1 (C), 121.9 (C), 118.24 (br, 2 peaks, C), 117.3 
(CH), 116.6 (CH), 110.0 (CH), 109.8 (CH), 108.99 (CH), 108.95 (CH), 82.2 (CH), 62.6 (C), 61.8 (C), 55.7 (C), 
50.98 (CH2), 50.97 (CH2), 42.8 (CH2), 42.7 (CH2), 35.8 (br, 2 peaks, CH2), 34.3 (CH3), 33.8 (CH3), 31.79 (CH3), 
31.75 (CH3), 20.25 (CH3), 20.23 (CH3); IR (thin film) 3354, 2930, 1710, 1610, 1359, 1162, 745 cm–1;  LRMS-
ESI (m/z) [M + H]+ calcd for C72H70N8O6S2H 1207.5; found, 1207.5; [a]23D +68, [a]23577 +69, [a]23546 +79, 
[a]23435 +157 (c = 0.33, CH2Cl2).  
(–)-Quadrigemine C (1). The procedure for hydrogenation of the enesulfonamide side chains and reductive 
cyclization for the ultimate conversion of tetrahydro intermediate to (–)-quadrigemine C that is reported herein 
(see the optimized general procedures described for the preparation of (R,R,R,R)-quadrigemine 7) has been 
found to be more reproducible than the procedure described previously.4 Using the optimized general procedure 
for hydrogenation of the enesulfonamide side chains, tetrahydro derivative 15 was prepared in >90% yield: 
[a]28D –144, [a]28577 –154, [a]28546 –177, [a]28435 –369, [a]28405 –492  (c = 0.10, CH2Cl2). Reduction of this 
intermediate with Na/NH3/t-BuOH gave (–)-quadrigemine (C) (8.3 mg, 24% overall yield from 12), [a]23D –67 
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(c = 0.2, CHCl3), HRMS-ESI (m/z) [M + H]+ calcd for C44H50N8H 691.4236; found, 691.4232; NMR and IR and 
optical rotation data were identical to those reported previously.4  
ent-(+)-Quadrigimine C (2). Following the optimized general procedure for hydrogenation of the 
enesulfonamide side chains, 104 mg of ent-12 was converted to tetrahydro derivative ent-15. This product was 
then directly subjected to the optimized reductive cyclization conditions to afford ent-(+)-quadrigemine C (2) 
(14 mg, 24%); IR (thin film) 3271, 3054, 2929, 2854, 2791, 1604, 1481, 1452 cm–1; HRMS-ESI (m/z) [M + H]+ 
calcd for C44H50N8H 691.4236; found, 691.4226; [a]23D +20, [a]23577 +17, [a]23546 +18, [a]23435 +48 (c = 0.15 , 
EtOH); [a]23D +70, [a]23577 +67, [a]23546 +60, [a]23435 +110 (c = 0.12 , CHCl3). 
4.2 Synthesis of meso-[2+2] quadrigemines 
Tetrahydro derivative of the major meso-dioxindole isomer 13. Following the optimized general procedure for 
hydrogenation of the enesulfonamide side chains, tetrahydro-13 (28.4 mg, 0.024 mmol, 98% yield) was 
obtained as a colorless solid from 29.6 mg of 13. 1H NMR (500 MHz, (CD3)2SO, 396K) d 7.50 (d, J = 8.1 Hz, 
4H), 7.33 (d, J = 7.6 Hz, 8H), 7.29–7.20 (m, 10H), 7.13 (d, J = 6.9 Hz, 2H), 7.09 (t, J = 7.1 Hz, 2H), 7.00 (d, J 
= 7.7 Hz, 2H), 6.85 (d, J = 7.7 Hz, 2H), 6.50 (br s, 2H), 6.43 (br s, 2H), 4.96 (d, J = 15.5 Hz, 2H), 4.85 (d, J = 
15.5 Hz, 2H), 4.78 (s, 2H), 4.29 (s, 2H), 2.96 (dt, J = 5.0, 12.6 Hz, 2H), 2.79 (br s, 2H), 2.70–2.66 (m, 2H), 2.61 
(s, 6H), 2.53–2.51 (m, 2H), 2.44–2.40 (m, 2H), 2.38 (s, 6H), 2.35–2.25 (m, 2H), 2.10–2.07 (m, 2H), 1.90 (s, 
6H), 1.80–1.77 (m, 2H); 13C NMR (125 MHz, (CD3)2SO, 396K) d 176.8 (C), 149.3 (C), 142.3 (C), 141.8 (C), 
135.5 (C), 134.8 (C), 130.0 (C), 128.8 (CH), 127.8 (CH), 127.5 (CH), 127.1 (C), 126.9 (CH), 126.7 (CH), 126.1 
(CH), 125.2 (CH), 123.8 (CH), 122.6 (CH), 121.9 (CH), 117.7 (C), 116.9 (CH), 108.7 (CH), 82.6 (CH), 61.7 
(C), 53.2 (CH2), 50.9 (C), 45.1 (CH2), 42.9 (CH2), 35.9 (CH2), 34.1 (CH3), 33.8 (CH3), 31.6 (CH2), 20.0 (CH3); 
IR (thin film) 3336, 3060, 2928, 2865, 2791, 1697, 1610, 1487, 1454, 1342 cm–1; LRMS-ESI (m/z) [M + H]+ 
calcd for C72H74N8O6S2H 1211.5; found, 1211.5. 
Tetrahydro derivative of the minor meso-dioxindole isomer 14. Following the optimized general procedure for 
hydrogenation of the enesulfonamide side chains, tetrahydro-14 (28.2 mg, 0.024 mmol, 94% yield) was 
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obtained as a colorless solid from 31.2 mg of dioxindole 14.  1H NMR (500 MHz, (CD3)2SO, 396K) d 7.45 (d, J 
= 8.2 Hz, 4H), 7.31 (d, J = 8.4 Hz, 4H), 7.27–7.21 (m, 8H), 7.18 (d, J = 7.6 Hz, 2H), 7.07 (t, J = 7.4 Hz, 2H), 
6.97(d, J = 7.8 Hz, 2H), 6.71 (br d, J = 7.2 Hz, 2H), 4.89 (d, J = 15.7 Hz, 2H), 4.78 (d, J = 15.7 Hz, 2H), 4.27 
(br s, 2H), 2.95–2.83 (m, 4H), 2.80 (s, 10H), 2.70–2.67 (m, 4H), 2.66–2.63 (m, 2H), 2.61 (s, 6H), 2.41–2.33 (m, 
10H), 2.27–2.23 (m, 2H), 2.21 (s, 4H), 1.86 (dd, J = 4.7 & 11.4 Hz, 2H); 13C NMR (125 MHz, (CD3)2SO, 
396K) d 177.0 (C), 142.3 (C), 141.9(C), 135.6 (C), 134.6 (C), 129.5 (C), 129.8 (CH), 127.7 (CH), 127.2 (CH),  
126.9 (C), 126.6 (CH), 126.5 (CH), 126.1 (CH), 125.2 (C), 124.3 (CH), 122.5 (CH), 121.7 (CH), 117.43 (C), 
108.8 (CH), 82.0 (CH), 62.1 (C), 53.6 (CH2), 50.9 (C), 45.4 (CH2), 42.8 (CH2), 35.3 (CH2), 34.3 (CH3), 33.9 
(CH3), 30.6 (CH2), 20.0 (CH3); IR (thin film) 3328, 3060, 2926, 2851, 2789, 1695, 1611, 1488, 1466, 1343 cm–
1; LRMS-ESI (m/z) [M + H]+ calcd for C72H74N8O6S2H 1211.5; found, 1211.5. 
Major meso-quadrigemine isomer.  Following the optimized general reductive cyclization procedure, 21 mg 
(0.017 mmol) of tetrahydro-13 was transformed to quadrigemine derived from the major meso-dioxindole Heck 
product 13. The solid was purified by preparative reverse-phase HPLC (Zorbax Extend C18, 100 x 21.2 mm, 
80:20 MeOH-H2O (1% NH4OH), 16 mL/min, UV detection at 254 nm) to afford 4.8 mg (40%) of the major 
meso-quadrigemine isomer (NOTE: relative configuration was not established; this product is either meso 
quadrigemine 3 or 4.)  (rt = 9.7 min) as a colorless solid. 1H NMR (500 MHz, (CD3)2SO, 376K) d 7.43-7.22 (m, 
7H), 6.92 (d, J = 7.5 Hz, 3H), 6.54 (d, J – 16.7 Hz, 2H), 6.17 (s, 2H), 5.65 (s, 3H), 5.13 (s, 1H), 4.96 (br s, 1H), 
4.27 (d, J = 6.6 Hz, 2H), 3.22 (s, 2H), 3.76 (br s, 7H), 2.57 (d, J = 6.9 Hz, 2H), 2.50-2.11 (m, 11H), 1.61 (s, 
3H), 1.32-1.28 (m, 4H) ; 13C NMR (125 MHz, (CD3)2SO, 376K) d 147.0 (C), 146.7 (C), 140.9 (CH), 134.3 (C), 
129.1 (CH), 128.2 (CH), 127.0 (CH), 120.5 (CH), 120.1 (C), 118.7 (CH), 107.4 (CH), 107.1 (CH), 100.5 (C), 
69.0 (CH), 60.6 (C), 58.0 (C), 54.0 (CH2), 48.0 (CH2), 37.7 (CH2), 37.2 (CH2), 28.2 (CH3), 22.9 (CH3); IR (thin 
film) 3365, 2923, 2851 1658, 1605, 1451, 1247, 1158, 1035, 744 cm–1; HRMS-ESI (m/z) [M + H]+ calcd for 
C44H50N8H 691.4236; found, 691.4244. 
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Minor meso-Quadrigemine isomer. Following the optimized general reductive cyclization procedure, 45 mg 
(0.037 mmol) of tetrahydro-14 was converted the quadrigemine derived from the minor meso-dioxindole Heck 
product 14. The resulting solid was purified by preparative reverse-phase HPLC (Zorbax Extend C18, 100 x 
21.2 mm, 80:20 MeOH-H2O (1% NH4OH), 10 mL/min, UV detection at 254 nm) to afford 4.0 mg (16%) of 
minor meso-quadrigemine isomer (NOTE: relative configuration was not established; this product is either 
meso quadrigemine 3 or 4.)  (rt = 70.7 min) as a colorless solid. 1H NMR (500 MHz, (CD3)2SO, 376K) d 6.98-
-6.93 (m, 4H), 6.60 (app t, J = 7.1 Hz, 2H), 6.54 (d, J = 7.8 Hz, 2H), 6.35 (br s, 2H), 5.88 (br s, 2H), 5.71 (br s, 
2H), 4.81 (s, 2H), 4.55 (br s, 2H), 3.55 (s, 2H), 2.96 (6H, br s), 2.66-2.58 (m, 4H), 2.50 (s, 4H), 2.08 (br s, 
10H), 1.91-1.89 (m, 2H), 1.82-1.81 (m, 2H), 1.27 (s, 2H); 13C NMR (125 MHz, (CD3)2SO, 376K) d 150.9 (C), 
149.3 (C), 133.0 (C) 131.8 (C), 126.8 (CH), 124.4 (CH), 123.9 (CH), 122.6 (C), 121.5 (CH), 116.7 (CH), 115.1 
(CH), 107.4 (CH), 85.1 (CH), 82.3 (CH), 61.8 (C), 59.6 (C), 51.1 (CH2), 37.8 (CH2), 36.3 (CH2), 34.8 (CH3), 
34.3 (CH3); HRMS-ESI (m/z) [M + H]+ calcd for C44H50N8H 691.4236; found, 691.4248; IR (thin film) 3271, 
2926, 2854, 2791, 1674, 1604, 1486, 1448, 1253, 1246, 1154, 1032, 743 cm–1 ; HRMS-ESI (m/z) [M + H]+ calcd 
for C44H50N8H 691.4236; found, 691.4237. 
4.3 Enantioselective total synthesis of [2+2] quadrigemines having a C2-symmetric core 
(R,R)-1,1'-Dimethyl-1,2,3,8,8a,1',2',3',8,8a'-octahydro-1H,1H'-[3a,3a']bi[pyrrolo[2,3-b]indolyl]-8,8'-
dicarboxylic acid di-tert-butyl ester (E1). Following the procedure employed in the meso series,4 a THF solution 
of sodium bis(trimethylsilyl)amide (15.3 mL, 30.6 mmol, 2 M) was added dropwise via syringe pump over 3 h 
to a solution of (+)-chimonanthine (2.95 g, 8.51 mmol),14c di-tert-butyldicarbonate (Boc2O) (8.16 g, 37.4 mmol), 
and THF (130 mL) at –78 °C. Upon completion of the addition the solution was maintained for 30 min at –78 
°C and then partitioned between saturated aqueous NH4Cl (50 mL) and EtOAc (50 mL).  The layers were 
separated and the aqueous phase was extracted with EtOAc (3 x 50 mL).  The combined organic layers were 
washed with brine (50 mL), dried over MgSO4, filtered, and concentrated under reduced pressure. The residue 
was purified by flash column chromatography (2:98 ® 5:95 MeOH/EtOAc) to yield the di-Boc derivative E1 as 
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a colorless foam (4.07 g, 87%): 1H NMR (600 MHz, (CD3)2SO, 373K) d 7.29 (d, J = 7.9 Hz, 2H), 7.04 (d, J = 
7.5 Hz, 2H), 6.98 (dd, J = 7.7, 0.9 Hz, 2H), 6.74 (t, J = 7.4 Hz, 2H), 2.71–2.67 (m, 2H), 2.47–2.44 (m, 2H), 2.44 
(s, 6H), 2.38–2.30 (m, 2H), 2.10–2.06 (m, 2H), 1.57 (s, 18H); 13C NMR (150 MHz, (CD3)2SO, 373K) d 152.3 
(C), 143.0 (C), 135.1 (C), 128.1 (CH), 123.1 (CH), 122.4 (CH), 115.4 (CH), 85.8 (CH), 81.1 (C), 61.1 (C), 52.9 
(CH2), 37.6 (CH3), 34.4 (CH2), 28.5 (CH3); IR (thin film):  2974, 2942, 2793, 1696, 1483, 1384, 1366, 1164 cm–
1; HRMS-ESI (m/z) [M + H]+ calcd for C32H42O4N4H 547.3284; found, 547.3267; [a]23D +163, [a]23577 +168, 
[a]23546 +191, [a]23435 +355  (c = 0.66, CH2Cl2). 
(R,R)-7,7'-diiodo-1,1'-dimethyl-1,2,3,8a,1',2',3',8a'-octahydro-[3a,3a']bi[pyrrolo[2,3-b]indolyl]-8,8'-dicarboxylic 
acid di-tert-butyl ester (E2). Following the procedure employed in the meso series,4 a cyclohexane solution of s-
BuLi (23.5 mL, 23.0 mmol, 0.98 M) was added dropwise over 1.5 h maintaining an internal temperature below 
–70 °C to a solution of dicarbamate E1 (2.79 g, 5.10 mmol), N,N,N’,N’-tetramethylethylenediamine47 
(TMEDA) (4.55 mL, 30.1 mmol) and Et2O (51 mL) at –78 °C. The solution was aged at –78 °C for 45 min.  
Then a solution of diiodoethane (14.5 g, 51.0 mmol) and Et2O (51 mL) was added dropwise by syringe. The 
resulting solution was maintained at –78 °C for 10 min, then warmed to 0 °C and maintained at 0 °C for 3 h. 
The mixture was partitioned between saturated aqueous Na2S2O4 (50 mL), saturated aqueous NaHCO3 (50 mL), 
and EtOAc (50 mL). The phases were separated and the aqueous layer was extracted with EtOAc (3 x 50 mL). 
The combined organic layers were washed with brine (100 mL) dried over MgSO4, filtered, and concentrated 
under reduced pressure. The residue was purified by flash column chromatography (2:1®0:100 hexane/EtOAc) 
to provide diiodide E2 as a beige solid (3.11 g, 84%): 1H NMR (600 MHz, (CD3)2SO, 373K) d 7.62 (d, J = 7.9 
Hz, 2H), 7.06 (d, J = 7.5 Hz, 2H), 6.74 (t, J = 7.7 Hz, 2H), 5.32 (s, 2H), 2.65–2.62 (m, 2H), 2.21–2.18 (m, 2H), 
2.05–2.02 (m, 2H), 1.79–1.75 (m, 2H), 1.59 (s, 18H); 13C NMR (150 MHz, (CD3)2SO, 373K) d 152.2 (C), 146.6 
(C), 139.40 (CH), 126.3 (CH), 124.1(CH), 88.9 (CH), 87.3 (C), 85.8 (C), 82.0 (C), 61.8 (C), 51.9 (CH2), 36.4 
(CH3), 35.7 (CH2), 28.4 (CH3);  mp = 197–199 °C; IR (thin film): 2975, 2796, 1702, 1442, 1367, 1352, 1299, 
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1245, 1158 cm–1; HRMS-ESI (m/z) [M + H]+ calcd for C32H40N4O4I2H 799.1218; found, 799.1224; [a]23D +186, 
[a]23577 +195, [a]23546 +225, [a]23435 +399, [a]23405 442 (c = 0.63, CH2Cl2). 
(R,R)-7,7'-diiodo-1,1'-dimethyl-1,2,3,8,8a,1',2',3',8,8a'-octahydro-1H,1H'-[3a,3a']bi[pyrrolo[2,3-b]indolyl] (18). 
Following the procedure employed in the meso series,4 neat TMSOTf (4.44 mL, 24.5 mmol) was added 
dropwise to a solution of diiodide E2 (4.45 g, 5.57 mmol) and CH2Cl2 (140 mL). The flask was left open to the 
air so that adventitious H2O would create a small amount of triflic acid. After 3 h, the solution was partitioned 
between saturated aqueous NaHCO3 (50 mL) and CH2Cl2 (100 mL). The phases were separated and the aqueous 
phase was extracted with CH2Cl2 (3 x 150 mL). The combined organic layers were dried over MgSO4, filtered, 
and concentrated under reduced pressure. The residue was purified by flash column chromatography with a 
gradient elution (9:1:0 ® 9:1:0.1 CH2Cl2/MeOH/Et3N) to yield 18 as a pale yellow foam (3.28 g, 99%): 1H 
NMR (500 MHz, (CD3)2SO, 376K) d 7.32 (d, J = 7.9 Hz, 2H), 7.20 (d, J = 7.3 Hz, 2H), 6.37 (t, J = 7.6 Hz, 2H), 
5.56 (s, 2H), 4.88 (br s, 2H), 3.04 (s, 1H), 2.78 (dt, J = 2.8, 7.5 Hz, 2H), 2.65 (br s, 3H), 2.61–2.55 (m, 2H), 
2.48–2.45 (m, 2H), 2.01–1.97 (m, 2H); 13C NMR (125 MHz, (CD3)2SO, 376K) d 152.3 (C), 135.1 (CH), 133.2 
(C), 122.7 (CH), 118.1 (CH), 82.2 (CH), 72.8 (C), 64.3 (C), 50.7 (CH2), 35.2 (CH2), 35.1 (CH3); IR (thin film) 
3402, 3062, 2845, 2789, 1596, 1470, 1246, 734 cm-1; HRMS-ESI (m/z) [M + H]+ calcd for C22H24N4I2H 
599.0168; found, 599.0167; mp = 193–195 °C; [a]23D +363, [a]23577 +383, [a]23546 +445, [a]23435 +909, [a]23405 
+1058 (c = 1.1, CH2Cl2). 
(R,R)-Dibutenanalide 19. Diiodide 18 (0.300 g, 0.501 mmol) and stannane 8 (1.31 g, 1.50 mmol) were 
combined in a round bottom flask and azeotroped in dry THF (3 x 6 mL). The mixture was then placed under 
vacuum (1.0 mmHg) for 30 min and then pumped into an inert atmosphere (N2) drybox. A stirbar followed by 
Pd(PPh3)448 (0.290 g, 0.251 mmol), LiCl (0.128 g, 3.01 mmol), and CuCl (0.250 g, 2.51 mmol) were added to 
the flask and the mixture was suspended in dry DMSO (17 mL). The flask was capped and stirred at room 
temperature in the drybox for 20 h. Upon completion the flask was removed from the drybox and the black 
solution was partitioned between 5% v/v aqueous solution of NH4OH (40 mL) and EtOAc (50 mL) and the 
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aqueous phase was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with water (3 
x 100 mL) followed by brine (1 x 100 mL).  The organic layer was dried over MgSO4, filtered, and concentrated 
under reduced pressure. The black residue was purified by flash column chromatography (10%KF/SiO245: 100:0 
CH2Cl2 ® 98:2 CH2Cl2/MeOH 94:5:1 ® CH2Cl2/MeOH/NH4OH ® 88:10:2 CH2Cl2/MeOH/NH4OH) to provide 
19 (0.741g, 98%) as a brown foam: 1H NMR (500 MHz, CDCl3) d complex due to the presence of multiple 
conformations on the NMR time-scale, see copy of spectra; 13C NMR (125 MHz, CDCl3) complex due to the 
presence of multiple conformations on the NMR time-scale, see copy of spectra (only major peaks listed) 
134.22, 129.7, 128.8, 128.6, 128.1, 128.0, 127.6, 127.4, 117.1, 83.9, 49.3, 35.8, 29.7, 27.8, 26.8, 21.5, 17.5, 
13.6; 19F NMR (376 MHz, CDCl3) –73.6; IR (thin film) 3415, 3063, 2863, 2791, 1649, 1494, 1455, 1421, 1339, 
1207, 1162, 893, 736 cm-1; LRMS-ESI (m/z) [M + H]+ calcd for C74H72N8F6O12S4H 1507.4; found, 1507.4; 
[a]23D +158, [a]23577 +167, [a]23546 +192, [a]23435 +433, [a]23405 403 (c = 0.46, CH2Cl2). 
Double enantioselective Heck cyclization of (R,R)-Dibutenanalide 19. Ditriflate 19 (0.200 g, 0.133 mmol) was 
azeotroped in benzene (3 x 2 mL) in a sealable Schlenk tube and placed under vacuum (1 mm) for 1 h. To the 
Schlenk flask was added a stirbar followed by Pd(OAc)2 (30 mg, 0.13 mmol), (R)-tol-BINAP (0.181 g, 0.266 
mmol), and N-Me-p-anisidine (0.143 g, 1.33 mmol). The flask was evacuated and backfilled with N2 (3 times). 
The mixture was then suspended in 1-methyl-2-pyrrolidinone (4.4 mL)49  and 1,2,2,6,6-pentamethylpiperidine50 
(97 µL, 0.53 mmol). The reaction mixture was degassed using the freeze–pump–thaw technique (3 cycles, 
liquid N2 cooling bath, 0.1 mmHg, backfill with N2). The heterogeneous brown-red mixture was heated to 80 °C 
for 16 h.  After cooling to room temperature the deep red solution was partitioned between a 20% w/w aqueous 
solution of NaCN (20 mL) and EtOAc (20 mL). The aqueous layer was extracted with EtOAc (3 x 20 mL). The 
combined organic layers were washed with water (3 x 40 mL) followed by brine (1 x 20 mL).  The organic 
layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by 
column chromatography (SiO2: 100:0 CH2Cl2 ® 97:3 CH2Cl2/MeOH ® 94:5:1 CH2Cl2/MeOH/NH4OH ® 
89:10:1 CH2Cl2/MeOH/NH4OH) to provide eluting first C1-symmetric dioxindole 21 (17.0 mg, 11%) followed 
by C2-symmetric dioxindole 20 (74.0 mg, 46%) as tan foams: (R,R,R,R)-dioxindole 20: 1H NMR (500 MHz, 
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(CD3)2SO, 376K) d 7.47 (d, J = 8.3 Hz, 4H), 7.33 (d, J = 8.1 Hz, 4H), 7.31 (dd, J = 7.8, 1.1 Hz, 2H), 7.20 (dd, J 
= 6.0, 1.9 Hz, 4H), 7.13 (dd, J = 5.7, 1.9 Hz, 8H), 7.01 (d, J = 7.1 Hz, 2H), 6.95 (d, J = 7.8 Hz, 2H), 6.70 (br d, 
J = 7.2 Hz, 2H), 6.62 (d, J = 14.3 Hz, 2H), 6.41 (d, J = 7.8 Hz, 2H), 6.14 (t, J = 7.7 Hz, 2H), 5.45 (d, J = 14.3 
Hz, 2H), 4.95 (d, J = 15.9 Hz, 2H), 4.90 (d, J = 15.9 Hz, 2H), 4.83 (br s, 4H), 2.90 (s, 6H), 2.63 (br m, 2H), 2.37 
(s, 6H), 2.37–2.31 (m, 2H), 2.21 (br s, 6H), 1.80–1.77 (m, 2H); 13C NMR (125 MHz, (CD3)2SO, 376K) d 176.3 
(C), 149.3 (C), 143.3 (C), 141.4 (C), 135.7 (C), 135.0 (C), 133.9 (C), 130.4 (CH), 129.4 (CH), 129.2 (CH), 
127.8 (CH), 126.5 (CH), 126.3 (CH), 125.9 (CH), 125.2 (CH), 124.7 (CH), 121.9 (CH), 121.7 (CH), 118.6 (C), 
117.0 (CH), 109.8 (CH), 109.0 (CH), 82.8 (CH), 78.5 (C), 62.5 (C), 55.7 (C), 50.1 (CH2), 42.5 (CH2), 34.9 
(CH2), 34.5 (CH3), 31.8 (CH3), 20.2 (CH3); IR (thin film) 3367, 3061, 3032, 2853, 2788, 1700, 1647, 1609, 
1466, 1355, 1246, 1159, 743 cm-1; HRMS-ESI (m/z) [M + H]+ calcd for C72H70N8O6S2H 1207.4938; found, 
1207.4950; [a]23D +28, [a]23577 +29, [a]23546 +34, [a]23435 +74 (c = 1.6, CH2Cl2). (S,R,R,R)-Dioxindole 21: 1H 
NMR (500 MHz, (CD3)2SO, 376K) d 7.51 (d, J = 13.6 Hz, 2H), 7.48 (d, J = 13.6 Hz, 2H), 7.44–7.19 
(overlapping multiplets, 16H), 7.11–7.03 (m, 6H), 6.98 (d, J = 7.9 Hz, 1H), 6.91 (d, J = 7.4 Hz, 1H), 6.74 (br d, 
J = 6.4 Hz, 1H), 6.63 (dd, J = 14.3, 3.7 Hz, 2H), 6.57 (br dd, J = 10.6, 7.9 Hz, 2H), 6.40 (t, J = 7.5 Hz, 1H), 
6.28 (t, J = 7.1 Hz, 1H), 5.45 (d, J = 14.3 Hz, 1H), 5.34 (d, J = 14.3 Hz, 1H), 5.01 (d, J = 9.1 Hz, 1H), 4.97 (s, 
2H), 4.85 (d, J = 15.8 Hz, 1H), 4.68 (br s, 1H), 4.44 (br s, 1H), 4.37 (br s, 1H), 2.92 (s, 3H), 2.90 (s, 3H), 2.65–
2.58 (m, 1H), 2.48–2.41 (m, 1H), 2.40 (s, 3H), 2.39 (s, 3H), 2.27–2.26 (m, 2H), 2.22–2.19 (m, 1H), 2.18 (s, 3H), 
2.02–1.98 (m, 1H), 1.82 (s, 3H), 1.77 (br dd, J = 11.9, 4.9 Hz, 1H), 1.69–1.66 (m, 1H); 13C NMR (125 MHz, 
(CD3)2SO, 376 K) d 176.3 (C), 175.9 (C), 149.2 (C), 148.4 (C), 143.35 (C), 143.31 (C), 141.4 (C), 141.3 (C), 
135.8 (C), 135.6 (C), 134.7 (C), 134.2 (C), 133.9 (C), 133.8 (C), 130.6 (C), 130.5 (C), 129.5 (CH), 129.4 (CH), 
129.28 (CH), 129.26 (CH), 127.94 (CH), 127.91 (CH), 127.8 (CH), 127.7 (CH), 127.0 (CH), 126.9 (CH), 126.7 
(CH), 126.5 (CH), 126.45 (CH), 126.0 (CH), 125.9 (CH), 125.7 (CH), 125.6 (CH), 124.5 (CH), 124.2 (CH), 
122.3 (CH), 122.1 (CH), 121.9 (CH), 119.1 (C), 118.7 (C), 117.2 (CH), 116.7 (CH), 110.2 (CH), 110.0 (CH), 
109.0 (CH), 108.9 (CH), 83.2 (CH), 83.0 (CH), 62.2 (C), 61.9 (C), 55.7 (C), 55.6 (C), 50.4 (CH2), 50.3 (CH2), 
42.8 (CH2), 42.6 (CH2), 35.2 (CH2), 35.1 (CH2), 34.5 (CH3), 34.3 (CH3), 31.84 (CH3), 31.78 (CH3), 20.27 (CH3), 
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20.24 (CH3); IR (thin film) 3378, 3060, 2857, 2790, 1703, 1609, 1465, 1356, 1159, 742 cm-1; LRMS-ESI (m/z) 
[M + H]+ calcd for C72H70N8O6S2H 1207.5; found, 1207.5; [a]23D +116, [a]23577 +121, [a]23546 +142, [a]23435 
+298, [a]23405 +276 (c = 0.80, CH2Cl2). 
Following the same procedure utilizing (S)-tol-BINAP instead of (R)-tol-BINAP, dibutenanilide 19 (0.282 mg, 
0.187 mmol) was converted into C2-symmetric dioxindole product 22 and C1-symmetric isomer 21. These 
products were purified by column chromatography (SiO2: 100:0 CHCl3 ® 98:2 CHCl3/MeOH ® 94:3:1 
CHCl3/MeOH/NH4OH ® 94:5:1 CHCl3/MeOH/NH4OH) to elute first C2-symmetric 22 (123 mg, 55%) 
followed by C1-symmetric 21 (87.0 mg, 39%) as tan foams. (S,R,R,S)-dioxindole 22: 1H NMR (500 MHz, 
(CD3)2SO, 376K) d 7.50 (d, J = 8.2 Hz, 4H), 7.40 (t, J = 6.3 Hz, 8H), 7.32 (t, J = 6.9 Hz, 4H), 7.28 (dt, J = 1.9, 
9.0 Hz, 4H), 7.07 (dd, 7.2, 14.8 Hz, 8H), 6.90 (d, J = 7.7 Hz, 2H), 6.68 (d, J = 7.9 Hz, 2H), 6.64 (d, J = 14.3 Hz, 
2H), 6.44 (t, J = 7.8 Hz, 2H), 5.34 (d, J = 14.3 Hz, 2H), 4.97 (d, J = 15.8 Hz, 2H), 4.95 (d, J = 15.7 Hz, 2H), 
4.39 (br d, 12.6 Hz, 2H), 2.90 (s, 6H), 2.40 (m, 8H), 2.25–2.19 (m 2H), 2.01–1.90 (m, 2H), 1.80 (s, 6H), 1.65–
1.62 (m, 2H); 13C NMR (125 MHz, (CD3)2SO, 376K) d 176.0 (C), 148.6 (C), 143.4 (C), 141.3 (C), 135.7 (C), 
133.8 (C), 130.5 (CH), 129.6 (CH), 129.3 (CH), 127.9 (CH), 127.7 (CH), 127.0 (CH), 126.9 (CH), 126.5 (C), 
126.99 (CH), 125.95 (CH), 124.2 (CH), 122.7 (CH), 122.1 (CH), 118.8 (C), 116.8 (CH), 110.2 (CH), 108.9 
(CH), 83.3 (CH), 61.9 (C), 55.7 (C), 50.6 (CH2), 42.8 (CH2), 35.3 (CH2), 34.2 (CH3), 31.8 (CH3), 20.3 (CH3); IR 
(thin film) 3417, 3376, 3061, 3032, 2867, 2791, 2244, 1708, 1650, 1609, 1485, 1465, 1357, 1247, 1160, 732 
cm-1; LRMS-ESI (m/z) [M + H]+ calcd for C72H70N8O6S2H 1207.5; found, 1207.5; [a]23D +147, [a]23577 +156, 
[a]23546 +184, [a]23435 +379, [a]23405 +201 (c = 0.81, CH2Cl2). 
4.4 Optimized general Procedure for Hydrogenation of the enesulfonamide side chains of the dioxindole 
Heck products  
Synthesis of the tetrahydro derivative of 20. A solution of 20  (140 mg, 0.116 mmol) in warm EtOH (4.0 mL) 
was added to a glass sleeve containing Pd(OH)2/C (0.28 g, 20 wt %), K2CO3 (130 mg, 0.928 mmol) and a 
stirbar. The sleeve was fitted inside a pressure reactor (Parr bottle 250 mL) and sealed. The Parr bottle was 
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charged with hydrogen gas (1000 psi) and heated to 80 °C for 24 h.  After cooling to room temperature and 
venting the mixture was filtered through Celite® and the filter cake was washed with CHCl3 saturated with NH3 
(20 mL). The washes were concentrated to afford the tetrahydro derivative of 20 (139 mg, 99%) as a colorless 
foam. An analytical sample was obtained by column chromatography (SiO2: 100:0 CH2Cl2 ® 97:3 
CH2Cl2/MeOH ® 94:5:1 CH2Cl2/MeOH/NH4OH ® 89:10:1 CH2Cl2/MeOH/NH4OH) to provide 121 mg (96%) 
of 21 as a colorless foam: 1H NMR (500 MHz, (CD3)2SO, 396K) d 7.54 (d, J = 8.2 Hz, 4H), 7.31 (overlapping 
signals d and m, d; J = 8.0 Hz, 8H), 7.18 (t, J = 7.2 Hz, 2H), 7.14 (t, J = 7.4 Hz, 2H), 7.10 (d, J = 7.2 Hz, 4H), 
7.02 (t, J = 6.8 Hz, 2H), 6.96 (t, J = 7.4 Hz, 4H), 6.89 (d, J = 7.9 Hz, 2H), 6.77 (d, J = 7.5 Hz, 2H), 6.33 (d, J = 
7.7 Hz, 2H), 6.04 (t, J = 7.6 Hz, 2H), 5.77 (br s, 2H), 4.97 (d, J = 15.8 Hz, 2H), 4.75 (d, J = 15.8 Hz, 2H), 3.07–
3.01 (m, 2H), 2.91–2.86 (m, 4H), 2.81 (br s, 4H), 2.63 (s, 6H), 2.38 (s, 6H), 2.37 (s, 6H), 2.32–2.23 (m, 2H), 
1.93–1.87 (m, 2H) 1.26 (br s, 2H); 13C NMR (125 MHz, (CD3)2SO, 396K) d 177.2 (C), 149.6 (C), 142.3 (C), 
141.9 (C), 135.3 (C), 134.6 (C), 129.4 (C), 128.8 (CH), 127.62 (CH), 127.57 (CH), 126.3 (CH), 126.2 (CH), 
126.1 (CH), 124.7 (CH), 124.5 (CH), 121.7 (CH), 121.4 (CH), 118.0 (C), 117.7 (C), 117.3 (CH), 108.9 (CH), 
82.8 (CH), 62.4 (C), 53.8 (C), 50.1 (CH2), 45.5 (CH2), 42.5 (CH2), 34.7 (CH2), 34.6 (CH2), 33.9 (CH3), 30.0 
(CH3), 20.0 (CH3); IR (thin film) cm-1; 3334, 3060, 3031, 2857, 2788, 1695, 1611 cm–1; HRMS-ESI (m/z) [M + 
H]+ calcd for C72H74N8O6S2H 1211.5251; found, 1211.5251; [a]23D –40, [a]23577 –43, [a]23546 –51, [a]23435 –102, 
[a]23405 –121 (c = 1.5, CH2Cl2). 
Tetrahydro derivative of 22. Following the optimized general procedure for the hydrogenation of the 
enesulfonamide side chains, 125 mg of 22 yielded 121 mg (96%) of the tetrahydro derivative of 22:  1H NMR 
(500 MHz, (CD3)2SO, 396K) d 7.51 (d, J = 7.9 Hz, 4H), 7.38–7.34 (m, 8H), 7.30–7.27 (m, 8H), 7.17 (d, J = 7.0 
Hz, 2H), 7.10 (t, J = 7.4 Hz, 2H), 7.03 (d, J = 7.6 Hz, 2H), 6.94 (d, J = 6.8 Hz, 2H), 6.72 (d, J = 7.8 Hz, 2H), 
6.42 (t, J = 7.3 Hz, 2H), 5.23 (s, 2H), 4.95 (d, J = 16.4 Hz, 2H), 4.89 (d, J = 15.3 Hz, 2H), 4.41 (s, 2H), 2.95–
2.91 (m, 2H), 2.84–2.80 (m, 4H), 2.65 (s, 6H), 2.49–2.42 (m, 2H), 2.39 (s, 6H), 2.36–2.31 (m, 2H), 2.27–2.24 
(m, 2H), 2.14–1.11 (m, 2H), 2.00 (s, 6H), 1.75–1.71 (m, 2H); 13C NMR (125 MHz, (CD3)2SO, 396K) d 177.0 
(C), 148.9 (C), 142.3 (C), 141.8 (C), 135.6 (C), 134.8 (C), 129.8 (C), 128.8 (CH), 127.8 (CH), 127.6 (CH), 
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126.9 (CH), 126.7 (CH), 126.2 (CH), 125.1 (CH), 124.0 (CH), 122.8 (CH), 121.9 (CH), 117.8 (C),  116.8 (CH), 
116.7 (C), 108.8 (CH), 83.8 (CH), 61.7 (C), 53.3 (C), 50.9 (CH2), 45.2 (CH2), 42.9 (CH2), 35.0 (CH3), 34.8 
(CH3), 33.9 (CH2), 31.5 (CH2), 20.0 (CH3); IR (thin film) 3320, 3057, 3033, 2851, 2790, 1692, 1610 cm-1; 
LRMS-ESI (m/z) [M + H]+ calcd for C72H74N8O6S2H 1211.5; found, 1211.5; [a]23D +254, [a]23577 +269, [a]23546 
+312, [a]23435 +625 (c = 1.1, CH2Cl2). 
Tetrahydro derivative of 21. Following the optimized general procedure for the hydrogenation of the 
enesulfonamide side chains, 230 mg of 21 yielded 224 mg (97%) of tetrahydro derivative of 21: 1H NMR (500 
MHz, (CD3)2SO, 396K) d 7.50 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 8.2 Hz, 2H), 7.37 (d, J = 7.1 Hz, 2H), 7.32 (d, J 
= 8.2 Hz, 4H), 7.30–7.23 (m, overlapping signals, 8H), 7.22 (d, J = 7.9 Hz, 2H), 7.16–7.07 (m, 4H), 7.02 (d, J = 
7.8 Hz, 1H), 6.98 (d, J = 7.8 Hz, 1H), 6.95 (d, J = 7.3 Hz, 1H), 6.80 (d, J = 7.3 Hz, 1H), 6.62 (d, J = 7.7 Hz, 
1H), 6.59 (d, J = 7.9 Hz, 1H), 6.36 (t, J = 7.5 Hz, 1H), 6.27 (t, J = 7.4 Hz, 1H), 5.44 (d, J = 3.9 Hz, 1H), 5.18 (s, 
1H), 4.96 (d, J = 15.6 Hz, 1H), 4.90 (s, 2H), 4.89 (d, J = 15.4 Hz, 1H), 4.70 (br s, 1H), 4.43 (br s, 1H), 3.03–
2.98 (m, 1H), 2.97–2.89 (m, 2H), 2.80 (br s, 3H), 2.68–2.61 (m, 1H), 2.66 (s, 3H), 2.65 (s, 3H), 2.44–2.40 (m, 
2H), 2.39 (s, 3H), 2.37 (s, 3H),  2.34–2.31 (m, 2H), 2.30 (s, 3H), 2.28–2.25 (m, 2H), 2.15–2.10 (m, 1H), 2.00 (s, 
3H), 1.84–1.81 (m, 1H), 1.75–1.72 (m, 1H); 13C NMR (125 MHz, (CD3)2SO, 396K) d 177.2 (C), 176.9 (C), 
149.5 (C), 148.8 (C), 142.30 (C, overlapping signal), 142.30 (C, overlapping signal), 141.89 (C), 141.86 (C), 
135.63 (C), 135.57 (C), 135.2 (C), 134.8 (C), 134.7 (C), 134.5 (C), 129.8 (C), 129.6 (C), 128.85 (CH, 
overlapping signal), 128.85 (CH, overlapping signal), 127.76 (CH, overlapping signal), 127.67 (CH, 
overlapping signal), 127.71 (CH), 127.6 (CH), 126.9 (CH), 126.7 (CH), 126.6 (CH), 126.3 (CH), 126.2 (CH), 
126.1 (CH), 124.9 (CH), 124.7 (CH), 124.4 (CH), 124.0 (CH), 122.3 (CH), 122.0 (CH), 121.84 (CH), 121.77 
(CH), 118.5 (C), 117.7 (CH), 117.4 (C), 116.8 (CH), 108.8 (CH), 108.7 (CH), 83.6 (CH), 82.9 (CH), 62.3 (C), 
61.9 (C), 53.7 (C), 53.3 (C), 50.6 (CH2), 50.3 (CH2), 45.4 (CH2), 45.2 (CH2), 42.9 (CH2), 42.8 (CH2), 35.0 
(CH2), 34.9 (CH2), 34.8 (CH3), 34.7 (CH3), 33.92 (CH3), 33.87 (CH3), 31.3 (CH2), 30.6 (CH2), 20.05 (CH3), 
20.03 (CH3); IR (thin film) 3334, 3058, 2852, 2789, 1693, 1610 cm-1; LRMS-ESI (m/z) [M + H]+ calcd for 
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C72H74N8O6S2H 1211.5; found, 1211.5; [a]23D +148, [a]23577 +155, [a]23546 +180, [a]23435 +360, [a]23405 +410 (c = 
0.87, CH2Cl2). 
4.5 Optimized general procedure for reductive cyclization to form dodecacyclic alkaloid products  
Preparation of (R,R,R,R)-quadrigemine 7. Caution!!! Ammonia gas is toxic and should only be used in a well-
ventilated fume hood. Ammonia was condensed in a 2-neck flask cooled to –78 °C and fitted with a cold finger 
filled with dry ice and isopropanol. After condensing ~20 mL NH3(l) a small piece of sodium (~25 mg) was 
added to provide a deep blue color. Using a wide-bore cannula approximately 10 mL of ammonia was distilled 
into another 2-neck flask cooled to –78 °C and fitted with a cold finger filled with dry ice and isopropanol. The 
tetrahydro derivative of 20 (68.0 mg, 0.056 mmol) in dry THF (3 mL) was added to the liquid NH3. Tert-
butanol (42 µL, 0.448 mmol) was added followed by slow addition of small pieces of sodium metal (65 mg, 2.8 
mmol). The heterogeneous solution was stirred vigorously at –78 °C as the solution slowly changed from clear 
yellow, green-brown, to blue. After persistence of the blue color for 20 min the reaction was quenched at –78 
°C by slowly adding solid NH4Cl (~190 mg). The blue color disappeared and a cloudy colorless precipitate 
formed. The flask was allowed to slowly warm to room temperature while open to the atmosphere and the 
ammonia permitted to evaporate. Water (20 mL) was added to the heterogeneous mixture and extracted with 
CHCl3 (sat with NH3; 3 x 30 mL). The combined organic layers were washed with brine (20 mL), dried over 
Na2SO4, filtered, concentrated under reduced pressure, and the residue was purified by reverse phase HPLC to 
yield (R,R,R,R)-quadrigemine 7 (8.8 mg, 23% from 20): Analytical reverse-phase HPLC (Zorbax Extend C18, 
250 x 4.6 mm), 72:28–>85:15 MeOH-H2O (1% NH4OH) over 40 min, 1.0 mL/min, UV detection at 254 nm (rt 
= 24.8 min); 1H NMR (500 MHz, (CD3)2SO, 376K) d 6.93 (app t, J = 7.1 Hz, 2H), 6.87 (d, J = 7.4 Hz, 2H), 
6.70-6.67 (m, 3H), 6.57 (app t, J = 7.0 Hz, 2H), 6.50 (d, J = 7.7 Hz, 2H), 6.20 (br app t, J = 7.7 Hz, 1H), 5.81 
(br s, 1H), 5.75 (br s, 1H), 4.77 (br s, 1H), 4.71 (br s, 2H), 3.89-2.82 (m, 7H), 2.61 (br s, 1H), 2.41 (s, 7H), 2.36 
(s, 5H), 2.26-2.23 (m, 2H), 1.83-1.79 (m, 3H), 1.34-1.25 (m, 6H), 0.85 (app t, J = 7.1 Hz, 2H);  1H NMR (500 
MHz, C6D6, 345K) d 7.10 (d, J = 6.9 Hz, 2H), 7.08 (d, J = 7.5 Hz, 1H),  7.01 (t, J = 7.6 Hz, 2H), 6.96 (br s, 1H), 
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6.76 (t, J = 7.3 Hz, 2H), 6.48 (br s, 1H), 6.42 (d, J = 7.5 Hz, 1H),  5.92 (s, 1H), 5.05 (s, 1H), 4.86 (s, 1H), 3.46 
(br s, 1H), 3.14–3.10 (m, 1H), 2.78 (t, J = 7.8 Hz, 2H), 2.70–2.68 (m, 3H), 2.60–2.56 (m, 3H), 2.55–2.51 (m, 
3H), 2.49 (s, 3H), 2.40 (br s, 5H), 2.25 (s, 4H), 1.94 (t, J = 8.1 Hz, 4H), 1.85 (dd, J = 5.0 & 11.1 Hz, 1H), 1.32–
1.28 (m, 3H); 13C NMR (125 MHz, C6D6, 345K) d 151.8 (C), 150.8 (C), 133.7 (C), 126.5 (CH), 125.7 (CH), 
119.6 (CH), 117.4 (CH), 109.8 (CH), 88.2 (CH), 84.8 (CH), 64.3 (C), 61.9 (C), 53.0 (CH2), 51.8 (CH2), 48.9 
(CH), 39.3 (CH2), 37.4 (CH2), 36.2 (CH3), 35.9 (CH3), 30.7 (C), 29.5 (CH), 18.1 (C); IR (thin film) 3379, 3270, 
3053, 2930, 2855, 2789, 1604, 1485, 1466, 1248, 1153, 1036, 908, 737 cm-1; HRMS-ESI (m/z) [M + H]+ calcd 
for C44H50N8H 691.4236; found, 691.4237; [a]23D +277, [a]23577 +283, [a]23546 +328, [a]23435 +656 (c = 0.20, 
EtOH). 
(S,R,R,S)-quadrigemine (5). Following the optimized general for the reductive cyclization, the tetrahydro 
derivative of 22 (71 mg, 0.059 mmol) was converted to 5 (11.9 mg, 29%): Analytical reverse-phase HPLC 
(Zorbax Extend C18, 250 x 4.6 mm), 72:28–>85:15 MeOH-H2O (1% NH4OH) over 40 min, 1.0 mL/min, UV 
detection at 254 nm: (rt = 29.4 min); 1H NMR (500 MHz, (CD3)2SO, 376K) d 6.98–6.94 (overlapping doublets, 
6H), 6.86 (d, J = 7.2 Hz, 2H), 6.61 (t, J = 7.1 Hz, 2H), 6.56 (d, J = 7.6 Hz, 2H), 6.37 (t, J = 7.5 Hz, 2H), 6.05 
(br s, 2H), 5.88 (br s, 2H), 4.84 (s, 2H), 4.72 (s, 2H), 2.94–2.90 (m, 8H), 2.76–2.69 (m, 2H), 2.41 (s, 6H), 2.37–
2.34 (m, 2H), 2.13 (s, 6H), 1.90–1.88 (m, 2H), 1.78–1.75 (m, 2H); 13C NMR (125 MHz, (CD3)2SO, 376K) d 
150.9 (C), 148.9 (C), 132.8 (C), 131.7 (C), 127.6 (CH), 126.8 (CH), 124.5 (CH), 123.8 (CH), 122.9 (C), 116.6 
(CH), 115.0 (CH), 107.5 (CH), 85.5 (CH), 83.2 (CH), 61.9 (C), 59.6 (C), 51.2 (CH2), 50.9 (CH2), 37.9 (CH2), 
35.4 (CH2), 34.8 (CH3), 34.7 (CH3); IR (thin film) cm-1; 3379, 3245, 3050, 2858, 2791, 1683, 1604, 1486 cm–1; 
HRMS-ESI (m/z) [M + H]+ calcd for C44H50N8H 691.4236; found, 691.4223; [a]23D +279, [a]23577 +289, [a]23546 
+332, [a]23435 +690 (c = 0.27, EtOH). 
(S,R,R,R)-Quadrigemine 6. Following the optimized general procedure for the reductive cyclization, the 
tetrahydro derivative of 21 (73 mg, 0.06 mmol)  was converted to 6 (11.9 mg, 29%): Analytical reverse-phase 
HPLC (Zorbax Extend C18, 250 x 4.6 mm), 72:28–>85:15 MeOH-H2O (1% NH4OH) over 40 min, 1.0 mL/min, 
 34 
UV detection at 254 nm: (rt = 27.3 min);  1H NMR (500 MHz, (CD3)2SO, 376K) d 6.98 (d, J = 7.1Hz, 2H), 6.95 
(d, J = 3.3 Hz, 1H), 6.93 (d, J = 7.2 Hz, 3H), 6.83 (d, J = 7.2 Hz, 1H), 6.79 (t, J = 8.1 Hz, 2H), 6.62–6.57 (m, 
2H), 6.54 (dd, J = 5.7, 7.1 Hz, 2H), 6.34 (t, J = 7.2 Hz, 1H), 6.28 (t, J = 7.3 Hz, 1H), 6.00 (s, 1H), 5.86 (s, 1H), 
5.82 (s, 1H), 5.75 (s, 1H), 4.80 (s, 2H), 4.69 (br s, 1H), 4.56 (br s, 1H), 2.68–2.61 (m, 3H), 2.47- 2.43 (m, 5H), 
2.41 (s, 3H), 2.39 (s, 3H), 2.33 (s, 3H), 2.31–2.26 (m, 2H), 2.14–2.11 (m, 1H), 2.10 (s, 3H), 1.89–1.82 (m, 3H), 
1.77–1.73 (m, 1H); 13C NMR (125 MHz, (CD3)2SO, 376K) d 151.9 (C), 149.9 (C), 127.9 (C), 125.7 (C), 117.7 
(CH), 117.5 (C), 116.4 (CH), 116.0 (CH), 108.5 (CH), 87.1 (CH), 86.5 (CH), 84.3 (CH), 83.9 (CH), 70.5 (CH), 
63.0 (C), 60.7 (C), 52.3 (CH2), 51.8 (CH2), 39.0 (CH2), 38.9 (CH2), 36.2 (CH3), 35.9 (CH3); IR (thin film) 3378, 
3055, 2852, 2791, 1698, 1603, 1486, 1456 cm–1; HRMS-ESI (m/z) [M + H]+ calcd for C44H50N8H 691.4236; 
found, 691.4237; [a]23D +347, [a]23577 +367, [a]23546 +435, [a]23435 +854 (c = 0.10, EtOH). 
Supplementary Information Available: Copies of 1H and 13C NMR spectra and HPLC traces, a description of 
general experimental details, summary of optical rotations reported for quadrigemine C, and HPLC and CD 
comparisons of synthetic and natural quadrigemine C. 
 
Acknowledgements 
     This research was supported by NIH grants (R01-HL25854 and R01-GM098601) and an NIH postdoctoral 
fellowship to T.L.M.-D. (F32-GM09660). NMR and mass spectra analyses were obtained at UC Irvine using 
instrumentation acquired with the assistance of NSF and NIH Shared Instrumentation programs. We thank Dr. 
Eike Hupe and Dr. Matthew Weiss for early studies in this area, and Dr. Philip Dennison and Dr. John Greaves, 
UC Irvine, for their assistance with NMR and mass spectrometric analyses. We are grateful Professor Françoise 
Guéritte-Voegelein for a sample of natural quadrigemine C and Professor Luisella Verotta for providing a 
sample of the crude Psychotria muscosa extract. Biological screening at the City of Hope was supported in part 
by NIH P30-CA22572 and the Drug Discovery and Structural Biology Core facility.  
 
 35 
References 
 
1 (a) Anthoni, U.; Christophersen, C.; Nielsen, P. H. in Alkaloids: Chemical and Biological Perspectives, Vol. 
13, Pelletier, W. S., Ed.; Pergammon: New York, 1999; pp 163–236. (b) Hino, T.; Nakagawa, M. In Alkaloids: 
Chemistry and Pharmacology, Vol. 34, Brossi, A., Ed.; Academic Press: New York, 1989; pp 1–75. (c) 
Sévenet, T.; Pusset, J.  in The Alkaloids: Chemistry and Pharmacology, Vol. 48, Cordell, G. A., Ed. , Academic 
Press: New York, 1996, pp 1–73. 
2 Steven, A.; Overman, L. E. Angew. Chem. Int. Ed. 2007, 46, 5488–5508. 
3 For reviews of recent synthetic studies, see: (a) Schmidt, M. A.; Movassaghi, M. Synlett 2008, 313–324. (b) 
Ruiz- Sanchis, P.; Savina, S. A.; Albericio, F.; Álvarez, M. Chem. Eur. J. 2011, 17, 1388–1408. (c) Tadano, S.; 
Ishikawa, H. Synlett 2014, 157–162; and reference 2. 
4 To date, the only total synthesis of a dodecacyclic members of these alkaloids is our total synthesis of (–)-
quadrigemine C, see: Lebsack, A. D.; Link, J. T.; Overman, L. E.; Stearns, B. A. J. Am. Chem. Soc. 2002, 124, 
9008–9009. 
5 Parry, K. P.; Smith, G. F. J. Chem. Soc., Perkin Trans. 1 1978, 1671–1682. 
6 Parry, K. P. “Alkaloids from Hodgkinsona frutescens. The Stucture of the Quadrigemines.” Ph.D. Thesis, 
University of Manchester, Manchester, UK, 1968.  
7 The 3a¢–3a² bond lengths of meso-chimonanthine and (–)-chimonanthine dihydrobromide, determined by 
single-crystal X-ray crystallography, are significantly elongated: 1.556 and 1.582 Å, respectively; see: Link, J. 
T.; Overman, L. E. J. Am. Chem. Soc. 1996, 118, 8166–8177; Grant, I. J.; Hamor, T. A.; Robertson, J. M.; Sim, 
G. A. J. Chem. Soc. 1965, 5678–5696. 
8 Clayton, E.; Reed, R. I.; Wilson, J. M. Tetrahedron 1962, 18, 1495–1501. 
9 (a) Libot, F.; Miet, C.; Kunesch, N.; Poisson, J. E.; Pusset, J.; Sévenet, T. J. Nat. Prod. 1987, 50, 468–473. (b) 
Guértte-Voegelein, F.; Sévenet, T.; Pusset, J.; Adeline, M.-T.; Gillet, B.; Beloeil, J.-C.; Guénard, D.; Potier, P.; 
Rasolonjanahary, R.; Kordon, C.  J. Nat. Prod. 1992, 55, 923–930. (c) Jannic, V.; Guéritte, F.; Laprévote, O.; 
Serani, L.; Martin, M.-T.; Sévenet, T.; Potier, P. J. Nat. Prod. 1999, 62, 838–843. (d) Verotta, L.; Pilati, T.; 
Tatò, M.; Elisabetsky, E.; Amador, T. A.; Nunes, D. S. J. Nat. Prod. 1998, 61, 392–396. 
10 Roth, A. Thése de Doctorat de 3éme cycle, Université Louis Pasteur, Strasbourg, 1984. 
11 Fridrichsons, J.; Mackay, M. F.; Mathieson, A. McL. Tetrahedron 1974, 36, 85–92. 
 
12 From initial degradation studies by Parry and Smith, quadrigemine A was believed to be the R,S,R,R isomer 
that was potentially contaminated with a diastereomer or meso compound resulting in a lower than expected 
optical rotation, see ref. 5. 
13 For a review of the use of enantioselective intramolecular Heck reactions in total synthesis, see: (a) Dounay, 
A.; Overman, L. E. “The Asymmetric Intramolecular Mizoroki-Heck Reaction in Natural Product Synthesis.” In 
The Mizoroki-Heck Reaction. M. Oestreich, Ed.; Wiley–VCH, West Sussex, UK, 2009, Ch 16., pp 533–568. 
For a review of using Heck reactions to desymmetrize precursors, see; (b) Shibasaki, M.; Ohshima, T. 
“Desymmetrizing Heck Reactions” In The Mizoroki-Heck Reaction. M. Oestreich, Ed.; Wiley–VCH, West 
Sussex, UK, 2009, Ch 13, pp 463–483.  
14 Stereocontrolled enantioselective total syntheses of (+)- or (–)-chimonanthine or (+)- or (–)-folicanthine:  (a) 
 36 
 
Overman, L. E.; Paone, D. V.; Stearns, B. A. J. Am. Chem. Soc. 1999, 121, 7702–7703; (b) Overman, L. E.; 
Larrow, J. F.; Stearns, B. A.; Vance, J. M. Angew. Chem. Int. Ed. 2000, 39, 213–215;  (c) Movassaghi, M.; 
Schmidt, M. A. Angew. Chem. Int. Ed. 2007, 46, 3725–3728; (d) Guo, C.; Song, J.; Huang, J.-Z.; Chen, P.-H.; 
Luo, S.-W.; Gong, L.-Z.  Angew. Chem. Int. Ed. 2012, 51, 1046– 1050; (e) Mitsunuma, H.; Shibasaki, M.; 
Kanai, M.; Matsunaga, S. Angew. Chem. Int. Ed. 2012, 51, 5217–5221; (f) Xie, W.; Jiang, G.; Liu, H.; Hu, J.; 
Pan, X.; Zhang, H.; Wan, X.; Lai, Y.; Ma, D. Angew. Chem. Int. Ed. 2013, 52, 12924–12927. 
15 Stereocontrolled total syntheses of meso-chimonanthine: (a) Link, J. T.; Overman, L. E. J. Am. Chem Soc. 
1996, 118, 8166–8167; (c) Lathrop, S. P.; Movassaghi, M. Chem. Sci. 2014, 5, 333–340; (c) Wada, M.; Murata, 
T.; Oikawa, H.; Oguri, H. Org. Biomol. Chem. 2014, 12, 298–306; and refs 14a and 14b. 
16 H. Ishikawa, H. Takayama, N. Aimi, Tetrahedron Lett. 2002, 43, 5637.  
17 Snell, R. H.; Woodward, R. L.; Willis, M. C. Angew. Chem. Int. Ed. 2011, 50, 9116–9119.  
18 For examples of Stille cross-couplings at room temperature and the effect of tri-2-furylphosphine, see: (a) 
Farina, V.; Krishnan, B. J. Am. Chem. Soc. 1991, 113, 9585–9595. For the role of CuI see: (b) Farina, V.; 
Kapadia, S.; Krishnan, B.; Wang, C.; Liebeskind, L. S. J. Org. Chem. 1994, 59, 5905–5911. (c) Liebeskind, L. 
S.; Fengl, R. W. J. Org. Chem. 1990, 55, 5359–5364. 
19 (a) Mee, S. P. H.; Lee, V.; Baldwin, J. E. Angew. Chem. Int. Ed. 2004, 43, 1132–1136. (b) Mee, S. P. H.; Lee, 
V.; Baldwin, J. E. Chem. Eur. J. 2005, 11, 3294–3308. 
20 Allred, G. D.; Liebeskind, L. S. J. Am. Chem. Soc. 1996, 118, 2748–2749. 
21 Fürstner, A.; Funel, J.-A.; Tremblay, M.; Bouchez, L. C.; Nevado, C.; Waser, M.; Ackerstaff, J.; Stimson, C. 
C. Chem. Comm. 2008, 2873–2875. 
22 Han, X.; Stoltz, B. M.; Corey, E. J. J. Am. Chem. Soc. 1999, 121, 7600–7605. 
23 For reviews of two-directional chain synthesis see: (a) Schreiber, S. L. Chem Scr. 1987, 27, 563–566. (b) 
Poss, C. S.; Schreiber, S. L. Acc. Chem. Res. 1994, 27, 9–17. (c) Magnuson, S. R. Tetrahedron, 1995, 51, 2167–
2213. (d) Willis, M. C. J. Chem Soc. Perkins 1 1999, 13, 1765–1784. (e) Mikami, K.; Yoshida, A. J. Syn. Org. 
Chem. Japan 2002, 60, 732–739. (e) Hoffmann, R. W. Angew. Chem. Int. Ed. 2003, 42, 1096–1109. 
24 (a) Vigneron, J. P.; Dhaenens, M.; Horeau, A. Tetrahedron, 1973, 29, 1055–1059. 
25  The relative configuration of the major and minor meso-dioxindole products was not possible by 
spectroscopic means. In addition, we were unsuccessful in crystallizing the two meso-quadrigemines that were 
prepared from these diooxindole intermediates. As a result, the relative configuration of these two products (i.e., 
which is 3 and which is 4) is unknown. 
26 Conditions: 10 mol% Pd(OAc)2, 20 mol% (R)-tol-BINAP, 4.0 equiv PMP, MeCN at 80 °C.27  
27 Kodanko, J. J.; Overman, L. E. Angew. Chem. Int. Ed. 2003, 42, 2528–2531. 
28 Computational model of the lowest energy conformation of (–)-quadrigemine C identified by Monte Carlo 
conformational searching using the MMMF force field and final optimization by DFT calculation at the EDF2-
631G* level. Calculations performed using Spartan 14, Wavefunction, Inc. 
29 Hydrogenation catalysts such as Rh/Al2O3, Ru/Al2O3, Pt2O, Ir(COD)(PCy3)PyPF6, Pd/C, and Pd(OAc)2) 
evaluated using a H2 atmosphere or under transfer hydrogenation conditions were less effective.   
 37 
 
30 Preparation of Pd(OH)2/C involves washing with dilute AcOH, see: Pearlman, W. Tetrahedron Lett. 1967, 17, 
1663–1664. 
31 Kodanko, J. J.; Hiebert, S.; Peterson, E. A.; Sung, L.; Overman, L. E.; de Moura Linck, V.; Goerck, G. C.; 
Amador, T. A.; Leal, M. B.; Elisabetsky, E. J. Org. Chem. 2007, 72, 7909–7914. 
32 Rao, T. S.; Pandey, P. S. Synth. Commun. 2004, 34, 3121–3127. 
33 Comparison CD and HPLC data is available in the Supplementary Information. 
34 The origin of the apparent discrepancy between the levorotatory optical rotation in ethanol that we observe for 
ent-quadrigemine C, [a]23D –30 (c = 0.2), and that reported for natural quadrigemine C in methanol, [a]D +40 (c 
= 0.2),9d is unclear, as CD spectra of synthetic quadrigemine C and natural quadrigemine C in methanol under 
the same conditions are identical.33 Moreover, we observe [a]23D +20 (c = 0.2) for ent-quadrigemine C.  
35 (a) Overman, L. E.; Peterson, E. A. Angew. Chem. Int. Ed. 2003, 42, 2525–2528. (b) Overman, L. E.; 
Peterson, E. A. Tetrahedron, 2003, 59, 6905–6919. 
36  For formation of Ac2O with Pd(OAc)2 and Ph3P see, Amatore, C.; Jutand, A.; M’Barki, M. A. 
Organometallics 1992, 11, 3009–3013. 
37 Obtaining NMR spectra in d6-DMSO at 376K of the [2+2] qudrigemine products 1, 2, meso-3, meso-4, and 5–
7 resulted in some simplification of the spectra by reducing the number of significant conformers present. 
However, these samples gradually decomposed during extended acquisition time at this temperature. NMR 
samples, which were clear and colorless solutions at the outset, eventually turned dark brown; partial 
degradation under the analysis conditions could be confirmed by HPLC analysis. 
38 Verotta, L.; Peterlongo, F.; Elisabetsky, E.; Amador, T. A.; Nunes, D. S. J. Chromatogr. A 1999, 841, 165–
176. 
39 Extract was from P. muscosa collected at Benfica, Brazil in Feb 1997 by Verotta and co-workers. 
40 (a) Amador, T. A.; Elisabetsky, E.; Souza, D. O. Neurochem. Res. 1996, 21, 97–102. (b) Amador, T. A.; 
Verotta, L.; Nunes, D. S.; Elisabetsky, E. Planta Med. 2000, 66, 770–772. (c) Amador, T. A.; Verotta, L.; 
Nunes, D. S.; Elisabetsky, E.  Phytomedicine 2001, 8, 202–6. (d) Verotta, L.; Orsini, F.; Sbacchi, M.; 
Scheildler, M. A.; Amador, T. A.; Elisabetsky, E.  Bioorg. Med. Chem. 2002, 10, 2133–2142. 
41 Beretz, A.; Roth-Georger, A.; Corre, G.; Kuballa, B.; Anton, R.; Cazenave, J. P. Planta Med. 1985, 51, 300–
303. 
42 (a) Roth, A.; Kuballa, B.;  Bounthanh, C.; Cabalion, P.; Sévenet, T.; Beck, J. P.; Anton, R. Planta Med. 1986, 
52, 450–453. (b) Adjibadé, Y.; Kuballa, B.; Cabalion, P. Jung, M. L.; Beck, J. P.; Anton, R. Planta Med. 1989, 
52, 567–568. (c) Adjibadé, Y.; Saad, H.; Kuballa, B.; Beck, J. P.; Sévenet, T.; Cabalion, P.; Anton, R. J. 
Ethnopharmacol. 1990, 29, 127–136.  
43 Such strategies have generally been employed to elaborate acyclic chains, see reference 23. 
44 Prepared as described: Coulson, D. R. Inorg. Syntheses 1972, 13, 121–124. 
45 10% KF/SiO2 was prepared as described: Harrowven, D. C.; Guy, I. L. Chem. Comm. 2004, 1968–1969. 
46 NMR spectra were nearly identical to those obtained previously for the enantiomer.4 The slight changes 
observed likely result from differences in the concentrations of the NMR samples. 
 38 
 
47 TMEDA was distilled from CaH2 immediately prior to use. 
48 Prepared as describe by Coulson, D. R. Inorg. Syntheses 1972, 13, 121–124. 
49 Dried by first azeotroping with benzene, followed by distillation from 4Å MS under vacuum and stored over 
4Å MS.   
50 Dried by distillation under vacuum from CaH2. 
